Generex Biotechnology (GNBTQ) 10-Q 19 Jun 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Apr. 30, 2019	Jun. 19, 2019
Document And Entity Information
Entity Registrant Name	GENEREX BIOTECHNOLOGY CORP
Entity Central Index Key	0001059784
Current Fiscal Year End Date	--07-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Apr. 30, 2019
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		60,362,143

UNAUDITED CONDENSED INTERIM CON

UNAUDITED CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Apr. 30, 2019	Jul. 31, 2018
Current Assets:
Cash and cash equivalents	$ 1,407,837	$ 1,046,365
Accounts receivable, net	1,803,192	33,555
Inventory, net	250,021	12,075
Other current assets	218,819	96,251
Total Current Assets	3,679,869	1,188,246
Property and equipment	556,276	31,536
Notes receivable - noncurrent	1,426,164
Call option		2,168,211
Goodwill and Intangible assets	48,323,164	3,187,757
Patents, net	21,362	23,280
Other assets, net	29,421	7,824
TOTAL ASSETS	54,036,256	6,606,854
Current Liabilities:
Accounts payable and accrued expenses	19,863,047	11,044,774
Notes payable, current	7,029,049	320,000
Loans from related parties	13,200	13,864,241
Other current liabilities	4,702
Deferred tax liability	1,929,955
Total Current Liabilities	28,839,953	25,229,015
Other noncurrent liabilities	2,233
Derivative liability - convertible notes	3,937,513
Derivative liability - warrants	257,478
Derivative liability - downside protection	6,994,450
Common stock payable	201,294
Warrants to be issued		24,962,507
Total Liabilities	40,232,921	50,191,522
Redeemable non-controlling interest	4,073,898
Stockholders' Equity (Deficiency)
Common stock, $.001 par value; authorized 750,000,000 shares at April 30, 2019 and July 31, 2018; 60,362,163 and 22,430,121 issued and outstanding at April 30, 2019 and July 31, 2018, respectively	60,362	22,430
Common stock payable		2,168,951
Additional paid-in capital	400,844,512	368,388,265
Accumulated deficit	(413,941,958)	(409,386,468)
Accumulated other comprehensive income	807,764	798,422
Non-controlling interest	21,958,757	(5,576,272)
Total Stockholders' Equity (Deficiency)	13,803,335	(43,584,668)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)	54,036,256	6,606,854
Series H Convertible Preferred Stock
Stockholders' Equity (Deficiency)
Convertible Preferred Stock		3
Regentys Series A Redeemable Convertible Preferred Stock [Member]
Stockholders' Equity (Deficiency)
Convertible Preferred Stock
Olaregen Series A Preferred Stock [Member]
Stockholders' Equity (Deficiency)
Convertible Preferred Stock
Series I Convertible Preferred Stock
Stockholders' Equity (Deficiency)
Convertible Preferred Stock		$ 1

UNAUDITED CONDENSED INTERIM C_2

UNAUDITED CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Apr. 30, 2019	Jul. 31, 2018
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	60,362,163	22,430,121
Common stock, shares outstanding	60,362,163	22,430,121
Series H Convertible Preferred Stock
Convertible preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	109,000	109,000
Convertible preferred stock, shares issued	0	63,000
Series I Convertible Preferred Stock
Convertible preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	6,000	6,000
Convertible preferred stock, shares issued	0	6,000
Regentys Series A Redeemable Convertible Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	2,793,192	2,793,192
Olaregen Series A Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	592,683	0
Convertible preferred stock, shares issued	592,683	0

UNAUDITED CONDENSED INTERIM C_3

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Revenue
Revenue, net	$ 1,055,626		$ 6,217,039	$ 2,218
Sales	37,300		37,300
Licensing income				700,000
Total Revenue	1,092,926		6,254,339	702,218
Cost of Goods Sold	1,264,964		4,147,264
Gross (Loss) Profit	(172,038)		2,107,075	702,218
Operating expenses
Research and development	472,010	307,420	1,463,015	696,099
General and administrative	8,656,877	684,390	17,428,182	1,800,440
Total operating expenses	9,128,887	991,810	18,891,197	2,496,539
Operating loss	(9,300,925)	(991,810)	(16,784,122)	(1,794,321)
Other income (expense):
Interest expense	(2,328,703)	(149,590)	(4,591,639)	(426,780)
Interest income	2,855		3,623
Changes in fair value of contingent purchase consideration		4,573,493	15,147,591	23,350,122
Change in fair value of derivative liability	987,442		1,130,167
Change in fair value of downside protection	(570,112)		(570,112)
Impairment of long-lived assets			(99,519)
Other income, net	56,135		8,699
Net (Loss) Income	(11,153,308)	3,432,093	(5,755,312)	21,129,021
Net loss attributable to non-controlling interests	(839,419)	(103,794)	(1,199,822)	(313,261)
Net Income Available to Common Stockholders	$ (10,313,889)	$ 3,535,887	$ (4,555,490)	$ 21,442,282
Basic	$ (0.17)	$ 0.16	$ (0.10)	$ 0.96
Diluted	$ (0.17)	$ 0.06	$ (0.10)	$ 0.39
Basic	60,362,163	22,430,100	44,203,218	22,430,100
Diluted	60,362,163	54,447,036	44,203,218	54,447,036
Comprehensive Income :
Net income	$ (10,313,889)	$ 3,535,887	$ (4,555,490)	$ 21,442,282
Change in foreign currency translation adjustments	7,318	13,677	9,342	9,779
Comprehensive Income Available to Common Stockholders	$ (10,306,571)	$ 3,549,564	$ (4,546,148)	$ 21,452,061

UNAUDITED CONDENSED INTERIM C_4

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Preferred Stock	Common Stock	Stock Payable	Paid-In Capital	Accumulated Deficit	Other Comprehensive Income	Sub Total	Noncontrolling Interest	Redeemable Non-controlling Interest	Total
Balance at Jul. 31, 2017	$ 4	$ 1,068	$ 2,168,951	$ 368,409,627	$ (445,720,566)	$ 783,150	$ (74,357,766)	$ (5,518,465)		$ (79,876,231)
Balance (in shares) at Jul. 31, 2017	3,790	1,068,100
Net Income (loss)					21,442,282		21,442,282	(313,261)		21,129,021
Investment in subsidiary by noncontrolling interest								213,403		213,403
Currency translation adjustment						9,779	9,779			9,779
Balance at Apr. 30, 2018	$ 4	$ 1,068	2,168,951	368,409,627	(424,278,284)	792,929	(52,905,705)	(5,618,323)		(58,524,028)
Balance (in shares) at Apr. 30, 2018	3,790	1,068,100
Balance at Jan. 31, 2018	$ 4	$ 1,068	2,168,951	368,409,627	(427,814,171)	779,252	(56,455,269)	(5,602,556)		(62,057,825)
Balance (in shares) at Jan. 31, 2018	3,790	1,068,100
Net Income (loss)					3,535,887		3,535,887	(103,794)		3,432,093
Investment in subsidiary by noncontrolling interest								88,027		213,403
Currency translation adjustment						13,677	13,677			9,779
Balance at Apr. 30, 2018	$ 4	$ 1,068	2,168,951	368,409,627	(424,278,284)	792,929	(52,905,705)	(5,618,323)		(58,524,028)
Balance (in shares) at Apr. 30, 2018	3,790	1,068,100
Balance at Jul. 31, 2018	$ 4	$ 22,430	2,168,951	368,388,265	(409,386,468)	798,422	(38,008,396)	(5,576,272)		(43,584,668)
Balance (in shares) at Jul. 31, 2018	79,590	22,430,121
Net Income (loss)					(4,555,490)		(4,555,490)	(1,199,822)		(5,755,312)
Investment in subsidiary by noncontrolling interest								228,789		228,789
Conversion of preferred series H	$ (3)	$ 25,200		(25,197)
Conversion of preferred series H (in shares)	(63,000)	25,200,000
Conversion of preferred series I	$ (1)	$ 6,631		(6,630)
Conversion of preferred series I (in shares)	(16,590)	6,630,644
Elimination of non-controlling interest				(6,951,015)			(6,951,015)			(6,951,015)
Issuance of common stock payable		$ 6,068	(1,967,657)	1,961,589
Issuance of common stock payable (in shares)		6,068,517
Issuance of stock options				1,530,312			1,530,312			1,530,312
Conversion of debt to equity		$ 33		14,056,080			14,056,113			14,056,113
Conversion of debt to equity (in shares)		32,881
Conversion of debt to equity - Veneto				13,929,129			13,929,129			13,929,129
Antigen dividend				(1,070,456)			(1,070,456)	1,070,456
Issuance of warrants				9,032,435			9,032,435			9,032,435
Acquisition of NCI of Regentys								9,870,762		9,870,762
Acquisition of NCI of Olaregen								11,999,559		11,999,559
Acquisition of NCI of HDS								5,565,285		5,565,285
Reclassification of equity to liability			(201,294)				(201,294)			(201,294)
Redeemable non-controlling interest									4,073,898	4,073,898
Currency translation adjustment						9,342	9,342			9,342
Balance at Apr. 30, 2019		$ 60,362		400,844,512	(413,941,958)	807,764	(12,229,320)	21,958,757	4,073,898	13,803,335
Balance (in shares) at Apr. 30, 2019		60,362,163
Balance at Jan. 31, 2019		$ 60,362	201,294	387,380,368	(403,628,069)	800,446	(15,185,599)	21,683,698	4,073,898	10,571,997
Balance (in shares) at Jan. 31, 2019		60,362,143
Net Income (loss)					(10,313,889)		(10,313,889)	(839,419)		(11,153,308)
Investment in subsidiary by noncontrolling interest								44,020		44,020
Issuance of stock options				605,467			605,467			605,467
Extinguishment of debt - Veneto				13,929,129			13,929,129			13,929,129
Antigen dividend				(1,070,456)			(1,070,456)	1,070,456
Acquisition of NCI of Olaregen								2		2
Reclassification of equity to liability			(201,294)				(201,294)			(201,294)
Currency translation adjustment						7,318	7,318			7,318
Balance at Apr. 30, 2019		$ 60,362		$ 400,844,512	$ (413,941,958)	$ 807,764	$ (12,229,320)	$ 21,958,757	$ 4,073,898	$ 13,803,335
Balance (in shares) at Apr. 30, 2019		60,362,163

UNAUDITED CONDENSED INTERIM C_5

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss) Income	$ (5,755,312)	$ 21,129,021
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization	550,285	17,514
Impairment of long-lived assets	99,519
Impairment of goodwill
Stock compensation expense	1,530,312
Changes in fair value of contingent purchase consideration	(15,147,591)	(23,350,122)
Amortization of debt discount	1,128,613
Non-cash interest expense from issuance on debt (derivative)	959,974
Change in fair value of derivative liabilities - convertible notes	(1,034,180)
Change in fair value of derivative liabilities - convertible warrants	(95,986)
Change in fair value of derivative liabilities - downside protection	570,112
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable	735,317
Inventory	1,239,411	(2,011)
Accounts payable and accrued expenses	7,108,042	673,282
Accrued interest on notes receivable	(38,401)
Other current assets	106,160	(139,848)
Other assets, net	(21,597)
Other current liabilities	4,702
Other noncurrent liabilities	2,233
Net cash used in operating activities	(8,058,387)	(1,672,164)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(285,670)	(8,553)
Purchase of intangible assets	(26,487)
Disposal of property and equipment	252,012
Disposal of intangible assets	62,091
Cash received in acquisition of a business, net of cash paid	2,280,425
Net cash provided by (used in) investing activities	2,282,371	(8,553)
CASH FLOWS FROM FINANCING ACTIVITIES
Loan proceeds from related party	(3,305)	145,803
Payment of notes payable	(27,248)
Proceeds from note payable	5,929,910
Investment in subsidiary by noncontrolling interest	228,789	213,403
Net cash provided by financing activities	6,128,146	359,206
Effects of currency translation on cash and cash equivalents	9,342	9,779
Net increase (decrease) in cash and cash equivalents	361,472	(1,311,732)
Cash and cash equivalents, beginning of period	1,046,365	2,879,165
Cash and cash equivalents, end of period	1,407,837	1,567,433
Supplemental Disclosure of Cash Flow Information
Antigen dividend		320,000
Conversion of HDS debt and issuance of call option	14,056,113
Acquisition of Veneto through issuance of debt
Acquisition of Regentys through issuance of debt
Acquisition of Olaregen through issuance of debt

Organization of Business and Go

Organization of Business and Going Concern	9 Months Ended
	Apr. 30, 2019
Accounting Policies [Abstract]
Organization of Business and Going Concern	Note 1 – Organization of Business and Going Concern: Generex Biotechnology Corporation (“Generex” or the “Company”), was formed in the State of Delaware on September 4, 1997 and its year-end is July 31. It is engaged primarily in the research and development of drug delivery systems and the use of the Company’s proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator; and through the Company’s wholly-owned subsidiary, Antigen Express, Inc. (“Antigen”), has undertaken work on immunomedicines incorporating proprietary vaccine formulations. On January 18, 2017, the Company closed an Acquisition Agreement pursuant to which the Company acquired a 51% interest in NuGenerex Diagnostics LLC “NGDx,” formerly known as Hema Diagnostic Systems, LLC, a Florida limited liability company established in December 2000 to market and distribute rapid test devices including infectious diseases. Since 2002, NGDx has been developing an expanding line of rapid diagnostic tests (RDTs) including such diseases as Human Immunodeficiency Virus (HIV) – 1/2, tuberculosis, malaria, hepatitis, syphilis, typhoid and dengue as well as other infectious diseases. Subsequently, on December 1, 2018, the Company exercised its call option and closed the acquisition of the remaining 49% interest in NGDx to become a wholly owned subsidiary of the Company. On October 3, 2018, the Company entered into an Asset Purchase Agreement with Veneto Holdings, L.L.C. (“Veneto”) to purchase certain assets of Veneto and its subsidiaries. The Agreement bifurcated the closing. On October 3, 2018 (the “First Closing”), the Company purchased substantially all the operating assets of Veneto including (a)system of dispensing pharmacies, (b) one central adjudicating pharmacy, (c) a wholesale pharmaceutical purchasing company, and (d) an in-network laboratory in exchange for a secured promissory note in the principal amount of $15,000,000. On November 1, 2018 the Company consummated the acquisition of the Second Closing Assets, consisting primarily of Veneto’s management services organization business and two additional ancillary services. The aggregate price for the First Closing Assets and the Second Closing Assets was $30,000,000. The Company issued a promissory note in the principal amount of $35,000,000 (the “ New Note Amendment On March 28, 2019, the Company entered into an Amendment Agreement (the “ Amendment As a result of the Amended Agreement entered into on March 28, 2019 (“the Amendment In March 2019, the Company changed its business model to no longer utilize their existing pharmacies. This shift resulted in breaking their existing lease agreements with their pharmacies which resulted in a liability of $606,296 as of April 30, 2019 and disposing the majority of applicable leasehold improvements, reduction of employees and no longer holding and selling inventory. Going forward Veneto will conduct business exclusively through their management services organization and by entering into more ancillary provider service agreements with third party pharmacies as an effort to reduce fixed costs and salaries. This was made practicable due to the decrease in overall script volume coupled with delays in the Company being able to receive operating licenses from various government agencies. On January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest in both Regentys Corporation (“Regentys”) and Olaregen Therapeutix Inc. (“Olaregen”). Regentys is a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York based regenerative medicine company that is preparing to launch its proprietary, patented, wound conforming gel matrix, Excellagen, an FDA 510K cleared wound healing product. The terms of the Regentys acquisition included an upfront payment of $400,000, plus $14,600,000 to be paid according to a milestone-based schedule. The terms of the Olaregen acquisition included an upfront payment of $400,000, plus $11,600,000 to be paid according to a milestone-based schedule. Going Concern The accompanying unaudited condensed interim consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. The Company has experienced recurring net losses and negative cash flows from operations since inception and has an accumulated deficit of approximately $413 million and a working capital deficiency of approximately $25 million at April 30, 2019. The Company has funded its activities to date almost exclusively from debt and equity financings. The Company will continue to require substantial funds to implement its new investment acquisition plans. Management’s plans in order to meet its operating cash flow requirements include financing activities such as private placements of its common stock, preferred stock offerings, and issuances of debt and convertible debt instruments. Management is also actively pursuing financial and strategic alternatives, including strategic investments and divestitures, industry collaboration activities and strategic partners. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the balance sheet date. There are no assurances that such additional funding will be achieved and that the Company will succeed in its future operations. The unaudited condensed interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s inability to obtain required funding in the near future or its inability to obtain funding on favorable terms will have a material adverse effect on its operations and strategic development plan for future growth. If the Company cannot successfully raise additional capital and implement its strategic development plan, its liquidity, financial condition and business prospects will be materially and adversely affected, and the Company may have to cease operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Apr. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies: Revenue Recognition It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Revenue from the pharmacy services is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient using common carrier or delivered by the pharmacies own personnel). At the time of dispensing each pharmacy has a contract with the insurance payor (item (i)); the insurance payor has accepted the claim for reimbursement from the pharmacy (item ii) and informed the pharmacy how much will be paid for the prescription (item (iii)); the insurance payor is now legally obligated to make payment on the accepted claim within a given period proscribed by statute (item (iv)); and, the prescription has been taken from the pharmacy inventory, placed into an individually labeled container specific to the patient, and the patient is able to take possession of the prescription (item (v)). Shipment to or pick up by the patient is the first time that all criteria for revenue recognition have been met. Revenue from the laboratory services is recognized upon the completion of accessions (the requested laboratory test has been performed and the report has been issued to the requesting physician). After the test has been performed and reported, the insurance company and/or patient has an obligation to pay for medically necessary laboratory tests (items (i) and (ii)). Unlike the pharmacy services model, laboratory services are provided prior to insurance company approval; as a result, the seller’s price to buyer is not known until payment is provided (items (iii) and (iv). Based on historical collections, the Company estimates the expected revenues associated with similar tests and recognizes the revenue when testing results have been provided (v). Revenue from the provision of management services is recognized in accordance with the contractual terms of the relationship (item i); however, the current agreements in place typically specify that a percentage of the gross margin associated with the third-parties’ sales that the Company facilitates is to be remitted (iii), and as such, the revenue is considered earned upon completion of the third parties’ sales of such products (iv). Like pharmacy services described above, revenue is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient using common carrier or delivered by the pharmacies own personnel) (v). Provisions for estimated sales returns and uncollectible accounts are recorded in the period in which the related sales are recognized based on historical and anticipated rates. The Company determines whether it is the principal or agent for its retail pharmacy contract services on a contract by contract basis. In the majority of its contracts, the Company has determined it is the principal due to it: (i) being the primary obligor in the arrangement, (ii) having latitude in changing the product or performing part of the service, (iii) having discretion in supplier selection, (iv) having involvement in the determination of product or service specifications, and (v) having credit risk. The Company’s obligations under its client contracts for which revenues are reported using the gross method are separate and distinct from its obligations to the third-party pharmacies included in its retail pharmacy network contracts. Pursuant to these contracts, the Company is contractually required to pay the third-party pharmacies in its retail pharmacy network for products sold, regardless of whether the Company is paid by its clients. The Company’s responsibilities under its client contracts typically include validating eligibility and coverage levels, communicating the prescription price and the co-payments due to the third-party retail pharmacy, identifying possible adverse drug interactions for the pharmacist to address with the prescriber prior to dispensing, suggesting generic alternatives where clinically appropriate, and approving the prescription for dispensing. Although the Company does not have credit risk with respect to Retail Co-Payments or inventory risk related to retail network claims, management believes that all of the other applicable indicators of gross revenue reporting are present. For contracts under which the Company acts as an agent, revenue is recognized using the net method. In March 2019, the Company changed its business model to no longer utilize their existing pharmacies. This shift resulted in breaking their existing lease agreements with their pharmacies which resulted in a liability of $606,296 as of April 30, 2019 and disposing the majority of applicable leasehold improvements, reduction of employees and no longer holding and selling inventory. Going forward Veneto will conduct business exclusively through their management services organization and by entering into more ancillary provider service agreements with third party pharmacies as an effort to reduce fixed costs and salaries. This was made practicable due to the decrease in overall script volume coupled with delays in the Company being able to receive operating licenses from various government agencies. Cost of Goods Sold Income Taxes Inventories Property and Equipment Leasehold improvements The shorter of the expected useful life of the improvement or the lease term Computers and technological assets 3-5 years Machinery and equipment 3-5 years Furniture and fixtures 3-7 years Assets acquired through finance lease arrangements or long-term rental arrangements that transfer substantially all the risks and rewards associated with ownership of the asset to the Company (as lessee) are capitalized. Reclassifications to Prior Period Financial Statements and Adjustments Certain reclassifications have been made in the Company’s condensed interim consolidated financial statements of the prior year to conform to the current year presentation. These reclassifications have no impact on previously reported net income. Redeemable Non-Controlling Interest As a result of the acquisition of Regentys with redeemable convertible preferred stock classified as a mezzanine instrument outside of the its equity accounts, such amounts are reclassified as redeemable non-controlling interest as the carrying value determined by the purchase price allocation at the time of the acquisition of Regentys. Derivative Financial Instruments As a result of the early adoption of ASU 2017-11 in the second quarter of the fiscal year ended April 30, 2019, the Company has no derivative financials instruments with down round features classified as a liability at April 30, 2019. Adoption of New Accounting Standards We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effective dates during the periods reported and in future periods. The Company does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. • ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” • ASC 815-40 (formerly SFAS No. 133 “Accounting for derivative instruments and hedging activities”), requires that embedded derivative instruments be bifurcated and assessed, along with free-standing derivative instruments such as warrants, on their issuance date and in accordance with ASC 815-40-15 (formerly EITF-00-19 “Accounting for derivative financial instruments indexed to, and potentially settled in, a company’s own stock”) to determine whether they should be considered a derivative liability and measured at their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option pricing formula and present value pricing. At April 30, 2019, the Company adjusted its derivative liability to its fair value, and reflected the change in fair value, in its condensed interim consolidated statement of operations and comprehensive loss. • ASU 2016-08 “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net).” • ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing.” • ASU 2016-11, “Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF (Emerging Issue Task Force) Meeting.” • ASU 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.” • ASU 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers.” • ASU 2018-07, “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” • ASU 2017-13, “Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840) and Leases (Topic 842). Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and Rescission of Prior SEC Staff Announcements and Observer Comments.” The standards provide companies with a single model for use in accounting for revenue arising from contracts with customers that supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the model is to recognize revenue when control of the goods or services transfers to the customer, as opposed to recognizing revenue when the risks and rewards transfer to the customer under the existing revenue guidance. The guidance permits companies to either apply the requirements retrospectively to all prior periods presented, or apply the requirements in the year of adoption, through a cumulative adjustment. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The guidance was adopted as of August 1, 2018. The Company found that the adoption did not have a material effect on the Company’s condensed interim consolidated financial statements and related disclosures. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments—Overall: Recognition and Measurement of Financial Assets and Financial Liabilities In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. The guidance was adopted as of August 1, 2018 and did not have a material effect on the Company’s condensed interim consolidated financial statements and related disclosures. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, In January 2017, the FASB issued ASU 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business.” These amendments clarify the definition of a business. The amendments affect all companies and other reporting organizations that must determine whether they have acquired or sold a business. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The amendments are intended to help companies and other organizations evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This update is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The guidance was adopted as of August 1, 2018 and did not have a material effect on the Company’s condensed interim consolidated financial statements and related disclosures. In May 2017, the FASB issued ASU 2017-09, “Compensation-Stock Compensation” (Topic 718): Scope of Modification Accounting. The amendments provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718 Compensation-Stock Compensation. An entity should account for the effects of a modification unless all the following are met: 1. The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification. 2. The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified. 3. The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The ASU is effective for all entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. The guidance was adopted as of August 1, 2018 and did not have a material effect on the Company’s condensed interim consolidated financial statements and related disclosures. Recently Issued Accounting Standards In February 2016, the FASB issued ASU No. 2016-02, Leases In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. Topic 480, Distinguishing Liabilities from Equity In February 2018, the FASB issued ASU 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement”, which adds disclosure requirements to Topic 820 for the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for interim and annual reporting periods beginning after December 15, 2019. The Company is evaluating the effect that ASU 2018-13 will have on its condensed interim consolidated financial statements.

Loans from Related Parties

Loans from Related Parties	9 Months Ended
	Apr. 30, 2019
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Abstract]
Loan from Related Party	Note 3 - Loans from Related Parties NGDx received substantially all of its funding from a shareholder, who owned 98.9% of NGDx prior to the acquisition of NGDx by the Company. The loan is unsecured, matures on December 31, 2019 and bears interest at 0.75% per annum through January 19, 2017, and bears no interest thereafter. Upon acquisition of NGDx by the Company (see Note 9), the outstanding principal balance was $13,239,837 and total accrued interest of $191,869. This loan was subject to a call option (Note 9) which, if exercised, the principal and accrued interest through January 18, 2017 would be eliminated. Pursuant to the January 18, 2017 Acquisition, Mr. Berkman, previous owner of NGDx and debt holder, agreed, under certain conditions to transfer the remaining 49% of the NGDx equity to the Company for a consideration of $1.00. On December 1, 2018, the Company and Mr. Berkman entered into an Agreement, Assignment and Release, pursuant to which Mr. Berkman transferred the remaining NGDx equity interests to the Company, waiving and releasing any conditions to such transfer. NGDx is now a wholly owned subsidiary of the Company. In addition to the assignment of the NGDx interests, Mr. Berkman released these loans in exchange for shares of the Company’s common stock valued at the aggregate of such amount using the closing price for the common stock on November 30, 2018. The closing price was $18.99, resulting in 32,881 shares issuable to Mr. Berkman. This transaction resulted in Mr. Berkman’s advances of $624,404 plus the loan and call option which resulted in additional paid in capital of $13,431,705 which was reclassified to the Company’s stockholders’ equity as an extinguishment of debt for $14,056,109. Pursuant to the January 7, 2019 acquisition of Regentys Corporation (“Regentys”), the Company assumed $16,505 of loans payable to Regentys shareholders which had a principal balance of $13,200 as of April 30, 2019.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Apr. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 4 - Commitments and Contingencies: Pending Litigation The Company is a defendant in one legal proceeding relating to alleged breach of contract and claims against certain of the Company’s original buccal delivery patents. The Company is also a defendant in two legal proceedings brought by a former executive officer and her affiliate. These legal proceedings have been reported in the Company’s prior periodic reports. No activity has occurred in these cases in several years, and the Company now considers them dormant. In December 2011, a vendor of the Company commenced an action against the Company and its subsidiary, Generex Pharmaceuticals, Inc., in the Ontario Superior Court of Justice claiming damages for unpaid invoices including interest in the amount of $429,000, in addition to costs and further interest. The Company responded to this statement of claim and also asserted a counterclaim in the proceeding for $200,000 arising from the vendor’s breach of contract and detinue, together with interest and costs. On November 16, 2012, the parties agreed to settle this action and the Company has agreed to pay the plaintiff $125,000, following the spinout of its subsidiary Antigen, from the proceeds of any public or private financing related to Antigen subsequent to such spinout. Each party agreed to execute mutual releases to the claim and counterclaim to be held in trust by each party’s counsel until payment of the settlement amount. Following payment to the plaintiff, the parties agree that a Consent Dismissal Order without costs will be filed with the court. If the Company fails to make the payment following completion of any post-spinout financing related to Antigen or any other subsidiaries, the Plaintiffs may take out a judgment in the amount of the claim plus interest of 3% per annum and costs fixed at $25,000. This has been accrued in the unaudited condensed interim consolidated financial statements. On August 22, 2017, Generex received a letter from counsel for Three Brothers Trading LLC, d/b/a Alternative Execution Group (“AEXG”), claiming breach of a Memorandum of Understanding (“MOU”) between Generex and AEXG. The MOU related to AEXG referring potential financing candidate to Generex. The letter from AEXG counsel claimed that Generex’s acceptance of $3,000,000 in financing from Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney’s fees and costs. On December 2, 2018, an arbitrator awarded Three Brothers Trading LLC, d/b/a Alternative Execution Group (“AEXG”) an aggregate of $315,695 in damages, costs and fees as well as warrants exercisable for 84,000 shares of Generex Common Stock at an exercise price of $2.50 per share. The awards were made pursuant to claims under a Memorandum of Understanding (“MOU”) between Generex and AEXG related to AEXG referring potential financing candidate to Generex. AEXG filed a petition to confirm the arbitrator’s award in the United States District Court for the Southern District of New York. The petition includes a demand of $3,300,360 as the value of the Warrants. The arbitrator did not award the specific amount of $3.3 million, but only liquidated damages in the amount of $220,000 and the value of 84,000 warrants “as of today” (the date of the award) plus attorney’s fees, certain costs, prejudgment and post-judgment interest (which continues to run on a daily basis) and arbitration fees. As of April 30, 2019, the value of the warrants have a market value of $65,613. Between the warrants and the $220,000 of liquidated damages, the Company has accrued $285,613 related to this matter. On June 28, 2018, the Company was named in respect of a claim by Burrard Pharmaceutical Enterprises Ltd. and Moa’yeri Kayhan for unspecified damages and other remedies issued by the Supreme Court of British Columbia. The claim is made in connection with one advanced against Burrard and Kayhan by Middle East Pharmaceutical Factory L.L.C., a foreign corporation, for fraudulent or negligent misrepresentation. Middle East alleges that it was misled by Burrard and Kayhan into believing that Burrard had rights to distribute Generex product in the Middle East. Burrard and Kayhan allege that they did have rights in that regard, which the Company denies. The matter remains at the pleadings stage and the Company is investigating the facts. On October 26, 2018, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell and sold its Note Due October 26, 2019 (“Note”) in the principal amount of $682,000 . On March 21, 2019 Compass Bank filed suit against NuGenerex Distributions Solutions 2, L.L.C. in the District Court of Dallas County, Texas requesting damages of $3,413,000. In connection with the closing of the Veneto acquisition, Compass Bank had a lien on certain assets that were supposed to be transferred into the ownership of NuGenerex, a subsidiary of Generex. Those assets were never transferred due to regulatory impositions. Generex had listed Compass Bank as an intended third party beneficiary to the transaction in relation to the assets liened and Veneto ceased payments upon the loan which the lien generated from. Compass bank filed suit against 6 parties involved in the transaction to collect on the loan, including NuGenerex. NuGenerex’s position is the contract was frustrated by the assets that were liened were never transferred, NuGenerex did not receive any benefit from the agreement, and thus NuGenerex is not responsible to Compass Bank for repayment of a loan on assets not transferred. Generex intends to implead Brooks Houghton for indemnification who was retained to perform due diligence on the transaction. In May 2019 Brooks Houghton threatened litigation by way of a FINRA Dispute Resolution. Brooks Houghton, who the managing representative is Mr. Centonfanti a prior board member, was under contract to perform due diligence on the Veneto transaction, as well as other unrelated items. The Veneto transaction closed three times, each time with a reduction in price due to material negative circumstances. Brook Houghton, who was under contract to perform due diligence, claims their fee should be paid on the initial closing price not the ultimate resolution of the matter. The company offered to compensate Brooks Houghton pursuant to agreement, 3% on the most recent closing price for Veneto for which Brooks Houghton may have performed some level of work on, payable in kind, and Brooks Houghton declined the offer. Brooks Houghton is claiming $450,000 for the first closing of Veneto, $714,000 for the second closing of Veneto, $882,353 for the Regentys acquisition, and $705,882 for Olaregen. The company is awaiting service. As of April 30, 2019, the Company has accrued for the full $2,752,235 balance. With respect to all litigation, as additional information concerning the estimates used by the Company becomes known, the Company reassesses its position both with respect to accrued liabilities and other potential exposures. Commitments Lease Agreements There are rental agreements in effect at Hema Diagnostics Systems, Empire State Pharmacy Inc., Regentys Corporation and Olaregen Therapeutix Inc. which have the following commitments as of April 30, 2019: $44,700 remaining in fiscal year 2019, $82,469 in fiscal year 2020 and $9,403 in fiscal year 2021. Intellectual Property In connection with the Company’s acquisition of Olaregen, intellectual property was acquired that had a valuation of $650,000 prior to being acquired and revalued. This initial $650,000 valuation represented the initial payment remitted by Olaregen in accordance with the $4 million signed commitment agreement entered into with Activation Therapeutics, Inc. The remaining $3.35 million balance is to be paid in quarterly installments equal to 10% of quarterly net sales generated by Activation Therapeutics assuming the Exellagen average selling price per unit exceeds $800. In the event that the average selling price per unit is less than $800 per unit, cost of goods sold shall be excluded from the computation of net sales.

Net Income Per Share (EPS)

Net Income Per Share (EPS)	9 Months Ended
	Apr. 30, 2019
Accounting Policies [Abstract]
Net Income Per Share (EPS)	Note 5 - Net Income Per Share (“EPS”): Basic net income or loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was 16,016,231 for the three and nine months ended April 30, 2019. Three Months Ended April 30, Three Months Ended April 30, 2019 2018 Weighted average number of common shares outstanding – Basic 60,362,163 22,430,100 Potentially dilutive common stock equivalents — 32,016,936 Weighted average number of common and equivalent shares outstanding-Diluted 60,362,163 54.447,036 Nine Months Ended April 30, Nine Months Ended April 30, 2019 2018 Weighted average number of common shares outstanding – Basic 44,203,218 22,430,100 Potentially dilutive common stock equivalents — 32,016,936 Weighted average number of common and equivalent shares outstanding-Diluted 44,,203,218 54.447,036

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Apr. 30, 2019
Equity [Abstract]
Stockholders' Equity	Note 6 - Stockholders’ Equity: Common Stock On November 13, 2018, the Company declared a stock dividend on its outstanding Common Stock for stockholders of record date to be determined (the “Record Date”). As a result, all stockholders on the Record Date received twenty new shares of Common Stock for each share of Common Stock owned by them as of that date. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, and warrants including all share and per-share data, for all amounts and periods presented in the condensed interim consolidated financial statements. On January 18, 2017, the Company issued 1,117,431 shares of common stock for the acquisition of 51% of NGDx and is obligated to issue 4,830,000 shares of common stock upon the conclusion of the Company’s reverse stock split. On October 26, 2018, 4,830,000 shares were issued. On January 30, 2019, the Company declared a dividend to holders of Generex common shares of its subsidiary Antigen Express, Inc., d/b/a NuGenerex Immuno-Oncology. On February 25, 2019, Generex shareholders received a dividend of one share of Antigen Express, Inc. for every four shares of Generex common stock which amounted to an issuance of 15,076,849 shares, representing approximately 3.77% ownership of Antigen. The fair value of the shares issued amounted to $1,070,456 and was recorded as a dividend with a corresponding increases to noncontrolling interest. During the nine months ended April 30, 2019, 1,238,517 shares of common stock payable were issued. As of April 30, 2019, 349,545 shares remain to be issued resulting in common stock payable $201,294. Series H and Series I Convertible Preferred Stock The Company has authorized 109,000 shares of designated non-voting Series H Convertible Preferred Stock with a stated value of $1,000 per share and authorized 6,000 shares of designated non-voting Series I Convertible Preferred Stock with a stated value of $47.61 per share pursuant to the Purchase Agreement dated March 27, 2017. The Series H Preferred Stock was scheduled to be sold in four tranches to the Purchaser. Under the Securities Purchase Agreement, in the event the Purchaser failed to purchase 100% of the shares of Preferred Stock at any given Closing, the Company can decline to sell any further securities to the Purchaser (the “Purchase Agreement”). The Series H and Series I Convertible Preferred Stock are convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of $.12 per share. Neither Series H nor Series I Convertible Preferred Stock have special dividend rights. If the Company pays dividends on its common stock, the holders of the preferred stock will receive dividends in the amount they would have received had they converted the preferred stock to common stock. At closing of the first tranche on March 28, 2017, the Company issued 63,000 shares of Series H Preferred Stock for a purchase price of $3,000,000. The proceeds of this sale were paid directly on the Company’s behalf to Emmaus as an additional deposit under the Company’s Emmaus LOI. The full amount of such proceeds was repaid to the Company in July 2017 upon termination of the Emmaus LOI. On December 1, 2018, after payment of the dividend, B-H Sanford, LLC, converted all of its holding of the Company’ Series H Convertible Preferred Stock owned by it into 25,200,000 shares of common stock. Prior to payment of Generex’s 20 for 1 common stock dividend, on November 30, 2018, Joseph Moscato, the Company’s President and Chief Executive Officer, and Lawrence Salvo, a member of the Company’s Board of Directors, converted all shares of the Company’ Series I Convertible Preferred Stock owned by them. Mr. Moscato received 3,276,000 shares of the Company’s Common Stock upon conversion. Mr. Salvo received 3,354,645 shares of the Company’s Common Stock upon conversion. Non-controlling Interest Mr. Berkman agreed, under certain conditions to transfer the remaining 49% of the NGDx equity to the Company for a consideration of $1.00. On December 1, 2018, the Company and Mr. Berkman entered into an Agreement, Assignment and Release, pursuant to which Mr. Berkman transferred the remaining NGDx equity interests to the Company, waiving and releasing any conditions to such transfer. As of December 1, 2018, NGDx is a wholly owned subsidiary of the Company. During the nine months ended in April 30, 2019, there was a net loss attributable to the non-controlling interest (49%) in NGDx of $122,692 and contributions made of $133,679. As of April 30, 2019, and July 31, 2018, the non-controlling interest in NGDx was $0 and $5,576,272, respectively. Pursuant to the Company’s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161 shares of Regentys common stock. As of April 30, 2019, Regentys had a total of 18,623,278 shares of common stock and 2,793,192 Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest. Pursuant to the Company’s acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632 shares of Olaregen common stock. As of April 30, 2019, Olaregen had a total of 5,648,819 shares of common stock and 592,683 Series A voting preferred stock for a total of 6,241,502 total voting shares outstanding. As such, there are 2,958,870 of shares that belong to non-controlling interest shareholders which represents a 47.41% non-controlling interest. On November 1, 2018, the Company completed its second closing of Veneto Holdings, L.L.C. (“Veneto”) which granted the Company Rapport Services, LLC (“Rapport”) through the ownership of the units of Class B membership interests providing control of Rapport as only the Class B Member is entitled to elect the nominees to the Board of Managers, which constitute a one percent (1%) ownership in Rapport. The remaining interests represent a 99% non-controlling interest.

Redeemable Non-Controlling Inte

Redeemable Non-Controlling Interest	9 Months Ended
	Apr. 30, 2019
Notes to Financial Statements
Redeemable Non-Controlling Interest	Note 7 – Redeemable Non-Controlling Interest: Pursuant to the Company’s acquisition of 51% of the outstanding capital stock of Regentys, Regentys had authorized 7,500,000 shares of redeemable Series A Convertible Preferred Stock (“Preferred Stock A”), with a par value of $0.0001 and redemption value of $0.65 per share of which 2,793,192 Preferred Stock A was outstanding as of the date of acquisition and as of April 30, 2019. Preferred Stock may be converted into common stock at the initial conversion ratio of 1:1 which ratio shall be adjusted in accordance with stock dividends, splits, combinations and other similar events, including the sale of additional shares of common or preferred stock and the holders of Preferred Stock A are entitled to vote, together with the holders of Regentys common stock, on all matters submitted to stockholders of Regentys for a vote. At any time after November 1, 2026, the holders of the Company’s Series A Preferred Stock will have the right to require the Company to redeem all or a portion of their shares for cash at a redemption price equal to its liquidation value. Accordingly, this Preferred Stock A was valued to be $4,073,898 at the time of acquisition of Regentys and reclassified as Redeemable Non-Controlling Interest outside of stockholders’ deficit on the condensed interim consolidated balance sheets.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Apr. 30, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Note 8 - Stock-Based Compensation Stock Option Plans As of April 30, 2019, the Company had three stockholder-approved stock incentive plans under which shares and options exercisable for shares of common stock have been or may be granted to employees, directors, consultants and advisors. A total of 2,835,000 shares of common stock are reserved for issuance under the 2006 Stock Plan as amended (the 2006 Plan) and 240,000,000 shares of common stock reserved for issuance under the 2017 Stock Option Plan (the 2017 Plan) and 1,200,000 shares of common stock reserved for issuance under the 2019 Stock Option Plan (the 2019 Plan). At April 30, 2019, there were 2,823,450, 234,492,875, 1,200,000 shares of common stock reserved for future awards under the 2006 Plan, 2017 Plan and 2019 Plan, respectively. The Company issues new shares of common stock from the shares reserved under the respective Plans upon conversion or exercise of options and issuance of restricted shares. The 2006, 2017 and 2019 Plans (the Plans) are administered by the Board of Directors (the Board). The Board is authorized to select from among eligible employees, directors, advisors and consultants those individuals to whom options are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Board is also authorized to prescribe, amend and rescind terms relating to options granted under the Plans. Generally, the interpretation and construction of any provision of the Plans or any options granted hereunder is within the discretion of the Board. The Plans provide that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees and non-employee directors, advisors and consultants are eligible to receive options which are not ISOs, i.e. “Non-Qualified Options.” The options granted by the Board in connection with its adoption of the Plans were Non-Qualified Options. In addition, the 2006 Plan also provides for restricted stock grants. The fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model or the value of the services provided, whichever is more readily determinable. The Black-Scholes option pricing model takes into account, as of the grant date, the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option. The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan: Options Weighted Average Exercise Price per Share Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding - July 31, 2018 232,218 $ 1.46 0.22 380,247 Granted 6,650,625 0.56 Forfeited or expired (1,364,168 ) (0.37 ) Exercised — — Outstanding - April 30, 2019 5,518,675 $ 0.68 9.15 3,157,178 The intrinsic value is calculated as the difference between the market value and the exercise price of the shares on April 30, 2019. The market values as of April 30, 2019 was $1.14 based on the closing bid price for April 30, 2019. The 5,518,675 outstanding options at April 30, 2019 had a weighted average remaining contractual term of 9.15 years. There were 2,345,175 vested common stock options under the Plan for the period ended April 30, 2019. The compensation expense was $1,526,609 for the nine months ended April 30, 2019. There was additional compensation expense pertaining to the Regentys acquisition of $3,703 for the nine months ended April 30, 2019 for total compensation expense of $1,530,312. The Company had $1,728,688 of unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Plan at April 30, 2019 to be recognized over an average of 2.22 years. The Company granted 6,650,625 options during the nine months ended April 30, 2019 and none during the year ended July 31, 2018. The Company estimated the fair value of each stock option on the grant date using a Black-Scholes option-pricing model. Black-Scholes option-pricing models requires the Company to make predictive assumptions regarding future stock price volatility, recipient exercise behavior, and dividend yield. The Company estimated the future stock price volatility using the historical volatility over the expected term of the option. The following assumptions were used in the Black-Scholes option-pricing model: April 30, 2019 Exercise price $0.64 – 1.85 Expected term 5 to 10 years Risk-free interest rate 2.56% - 3.15 % Estimated volatility 135.2% - 222.2 % Expected dividend — Stock price at valuation date $0.64 – $1.85

Acquisitions

Acquisitions	9 Months Ended
	Apr. 30, 2019
Business Combinations [Abstract]
Acquisitions	Note 9 – Acquisitions: NuGenerex Diagnostics LLC: On January 18, 2017, the Company acquired a 51% interest in NuGenerex Diagnostics LLC (“NGDx”), formerly Hema Diagnostic Systems, LLC, pursuant to the Acquisition Agreement. At closing, the Company acquired 4,950 of NGDx’s 10,000 previously outstanding limited liability company units in exchange for 1,117,011 shares of Generex common stock valued at $253,721, plus 420 shares of Generex common stock issued to NGDx in exchange for 300 new limited liability company units. The Acquisition Agreement also provides the Company with a call option to acquire the remaining 49% of NGDx and a retirement of NGDx shareholder loans in the amount of $13,431,706 (including interest) (the “Call Option”) for the aggregate purchase price of $1. On November 30, 2018, the call option was exercised, and the Company acquired the remaining 49% of NGDx. Following the closing and the completion of Company’s reverse stock split, the Company was required to issue an additional 4,830,000 shares of common stock and issue a warrant to a former shareholder of NGDx to acquire 15,000,000 additional shares of Generex common stock for $2.50 per share. The issue of this warrant is contingent upon the Company obtaining approval from its shareholders for an increase in its authorized share capital. The total consideration was valued at $1,350,916 on the date of the acquisition. As of April 30, 2019, all warrants relating to this acquisition have been issued which resulted in additional paid in capital of $9,032,435. Fair Value of the NGDx Assets The intangibles assets acquired include In–Process Research & Development (“IPR&D”). The Fair Value of the IPR&D intangible asset using an Asset Cost Accumulation methodology as of January 18, 2017 (the “Valuation Date”) was determined to be $2,911,377. Intangible assets are generally amortized on a straight-line basis over the useful lives of the assets. The Company is currently not amortizing the in-process research and development until it becomes commercially viable and placed in service. At the time when the intangible assets are placed in service the Company will determine a useful life. The net purchase price of NGDx was determined to be as follows: Stock Price at Closing Shares Fair Value Purchase price: Common Stock at closing $ .23 1,117,011 $ 253,721 Common Stock after closing $ .23 420 95 Common Stock post reverse stock split $ .23 4,830,000 1,097,100 Total purchase price 5,947,431 $ 1,350,916 As of January 18, 2017, the issue of the warrant to acquire 15,000,000 additional common shares of Generex was contingent upon shareholder approval of an increase in the Company’s authorized capital stock. No warrant could be issued by the Company until such time that an increase in authorized capital has been approved. At the time of closing, management was not of the opinion that it is more likely than not that the warrant will be issued and the Call Option will be exercised, accordingly no values have been attributed to the warrant and Call Option at closing. During 2017, management made a redetermination and estimated that it was more likely than not that the shareholder approval to increase authorized share capital would be obtained and the Call Option would be exercised. On December 1, 2018, pursuant to the Acquisition Agreement the Company issued the warrant to 15,000,000 additional common shares of Generex to Stephen L. Berkman. The Warrant is exercisable until December 1, 2019 at an exercise price of $2.50 per share. The Warrant contains a provision prohibiting the exercise of the Warrant to the extent that, after exercise, Mr. Berkman would own more than 9.99% of the Company’s common stock. The Warrant was issued pursuant to the January 18, 2017 Acquisition Agreement among the Company, NuGenerex Diagnostics LLC (“NGDx”), formerly Hema Diagnostic Systems, LLC, Stephen L. Berkman and the other equity owners of NGDx. Simultaneously, on December 1, 2018, Company exercised the Call Option and acquired the remaining 49% non-controlling interest in NGDx. Accordingly, the fair values of the warrants and call option was updated through the issuance and exercise date and the change in the fair value of the contingent purchase consideration of a loss of $4,397,507 and a gain of $15,147,591 was recorded and included in the condensed interim consolidated statements of operations and comprehensive income for the nine-months ending April 30, 2019. The Company adopted a sequencing policy and determined that the warrants with fixed exercise price were excluded from derivative consideration. The remaining fair value of the call option and the warrant payable remaining at the time of exercise of the call option and issuance of the warrant was charged against additional paid-in capital as an elimination of non-controlling interest for a loss of $6,951,015. Fair Value Assumptions Used in Accounting for the Warrant The Company used the Black-Scholes option-pricing model to calculate the fair value of the warrant as of April 30, 2019. The Black-Scholes option-pricing model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. The key inputs used in the fair value calculations were as follows: December 1, 2018 July 31, 2018 Exercise price 2.50 2.50 Time to expiration 3.14 years 3.47 years Risk-free interest rate 3.01 % 2.77 % Estimated volatility 138.61 % 143.97 % Dividend — — Stock price at valuation date $ 0.9 $ 0.1 Fair Value Assumptions Used in Accounting for Call Option The Company used the Monte Carlo model to calculate the fair value of the call option as of nine months ended April 30, 2019. The valuations are based on assumptions as of the valuation date with regard to the value of the asset acquired net of impairment, the risk-free interest rate, the estimated volatility of the stock price in the future, the time to expiration and the stock price at the date of valuation. The following assumptions were used in estimating the value of the Call Option: December 1, 2018 July 31, 2018 Risk-free interest rate 2.52 % 2.44 % Estimated volatility 164.43 % 129.95 % Remaining Term 1.13 years 1.47 years Stock price at valuation date $ 0.9043 $ 0.0976 Grainland and Empire Pharmacies: On December 28, 2017, the Company through its wholly owned subsidiary NuGenerex, completed the acquisition of the assets and 100% of the membership interests of two pre-operational pharmacies, Empire State Pharmacy Holdings, LLC and Grainland Pharmacy Holdings, LLC, pursuant to the bills of sale for a consideration of $320,000 Promissory Note due and payable in full on June 28, 2018 bearing an annual interest rate of 3%. The note was extended by six months and set to mature with the same terms on December 28, 2018. The note remains active and interest has continued to accrue while new terms of the note are in process of being negotiated. We finalized our allocation of the purchase price as of January 31, 2019. The final allocation of the purchase price as of January 31, 2019, is as follows: Preliminary Allocation as of December 28, 2017 Allocation Adjustments Final Allocation Intangible assets (licenses) $ 276,380 $ — $ 276,380 Property and equipment 19,879 — 19,879 Computer software acquired 5,980 — 5,980 Leasehold Improvements 17,761 — 17,761 Total assets acquired 320,000 — 320,000 Consideration: Note Payable 320,000 320,000 Goodwill $ — $ — The entire value of the intangible assets represent the licenses obtained to operate a pharmacy in the respective state of each of the acquired pharmacies. Intangible assets are generally amortized on a straight-line basis over the useful lives of the assets. The Company is currently not amortizing the pharmacy license until the pharmacies becomes commercially viable and operations begin in the acquired pharmacies. At the time, when the licenses are placed in service, the Company will determine a useful life. Since acquisition, Grainland Pharmacy Holdings, LLC ceased to operate. Accordingly, the value allocated to its tangible assets, leasehold improvements and licenses acquired for $99,519 was charged to impairment of long-lived assets. Veneto: On October 3, 2018, the Company entered into an Asset Purchase Agreement (the “Agreement”) with Veneto Holdings, L.L.C. (“Veneto”) to purchase certain assets of Veneto. Effective as at October 3, 2018, NuGenerex Distribution Solutions, LLC assigned the Veneto Asset Purchase Agreement to NuGenerex Distribution Solutions 2, LLC. The sole member of that LLC is NuGenerex Management Services, Inc., a wholly-owned subsidiary of Generex Biotechnology Corporation. The aggregate purchase price for the Assets is $35,000,000 including the Promissory Note. At the Second Closing, the Company will pay the principal of the Promissory Note plus interest to Veneto, (i) $9,000,000 will be paid by the Company into a trust or other fiduciary account acceptable to Veneto to be used exclusively for satisfaction of certain contingent liabilities of Veneto and subsidiaries of Veneto not being acquired by the Company, (ii) $3,000,000 will be paid by the Company into an escrow account to secure potential obligations of Veneto in respect of the Second Closing date working capital and under the indemnification provisions of the Agreement and (iii) the balance will be payable directly to Veneto in cash. The Company had also entered into a temporary fee-for-service arrangement with Veneto and one of its subsidiaries for Veneto to provide management, personnel, operational, administrative and other services with respect to the First Closing Assets pending the Second Closing. At the Second Closing, all of Veneto personnel providing these services became employees or consultants of the Company, and, therefore, Veneto no longer provides these services. At the First Closing, the Promissory Note issued to Veneto in the original principal amount of $15,000,000 with interest at an annual rate of 5.0% and guaranteed by Generex and Joseph Moscato, and secured by a first priority security interest in the Company’s assets other than the First Closing Assets was subsequently cancelled upon the issuance of the new promissory note on the Second Closing in the principal amount of $35,000,000 with an annual of 12.0% and guaranteed by Generex and Joseph Moscato. On November 1, 2018 the Company consummated the acquisition of the Second Closing Assets, consisting primarily of Veneto’s management services organization business and two additional ancillary services. The aggregate price for the First Closing Assets and the Second Closing Assets was $30,000,000. The Company issued a promissory note in the principal amount of $35,000,000 (the “ New Note There was $62,500 of accrued interest on the first closing $15,000,000 note and an additional $1,716,129 of accrued interest on the second closing $35,000,000 promissory note for a total of $1,778,629 accrued interest through March 28, 2019 when the Company entered into an Amendment Agreement (the “ Amendment On March 28, 2019, the Company entered into an Amendment Agreement (the “ Amendment As a result of the Amended Agreement entered into on March 28, 2019 (“the Amendment Fair Value of the Veneto Acquisition The following table summarizes the allocation of the preliminary purchase price as of the Veneto acquisition as of the First Closing and the Second Closing: “First Closing” completed on October 3, 2018 “Second Closing” completed on November 1, 2018 Total Cash and cash equivalents $ 2,410,150 $ — $ 2,410,150 Accounts receivable, net 1,935,078 — 1,935,078 Inventory, net 1,068,856 — 1,068,856 Prepaid expenses 95,804 — 95,804 Property and equipment, net 652,590 — 652,590 Other receivables 1,014,316 — 1,014,316 Notes receivable - LT 1,387,763 — 1,387,763 Other assets, net 25,745 — 25,745 Intangible assets, net 35,603 7,110,000 7,145,603 Total assets acquired 8,625,905 7,110,000 15,735,905 Total current liabilities 2,509,887 — 2,509,887 Notes payable — 3,403,948 3,403,948 Total liabilities assumed 2,509,887 3,403,948 5,913,835 Net identifiable assets acquired 6,116,018 3,706,052 9,822,070 Goodwill 8,883,982 16,293,948 25,177,930 Total consideration transferred $ 15,000,000 $ 20,000,000 $ 35,000,000 The following table summarizes the allocation of the revalued purchase price as of the Veneto acquisition as of the First Closing and the Second Closing during the quarter ending April 30, 2019: “First Closing” completed on October 3, 2018 “Second Closing” completed on November 1, 2018 Total Cash and cash equivalents $ 2,410,150 $ — $ 2,410,150 Accounts receivable, net 1,430,638 — 1,490,638 Inventory, net 1,068,856 — 1,068,856 Prepaid expenses 95,804 — 95,804 Property and equipment, net 652,590 — 652,590 Other receivables 1,014,316 — 1,014,316 Notes receivable - LT 1,387,763 — 1,387,763 Other assets, net 25,745 — 25,745 Intangible assets, net 35,603 2,277,000 2,312,603 Total assets acquired 8,181,465 2,277,000 10,458,465 Total current liabilities 2,065,448 — 2,065,448 Notes payable — 3,403,948 3,403,948 Total liabilities assumed 2,065,448 3,403,948 5,469,396 Net identifiable assets acquired 6,116,017 (1,126,948 ) 4,989,069 Goodwill 13,585,769 Total consideration tranferred $ — $ — $ 18,574,838 The note receivable for $1,387,763 acquired during the first closing of Veneto on October 3, 2018 has since accrued additional interest and holds a balance of $1,426,164 as of April 30, 2019. The significant intangible assets identified in the purchase price allocation discussed above include developed software and technology, referral base (recurring revenue from the MSO investments and their use of Company owned pharmacies) and non-compete agreements with continued employment of key employees. Tradenames and trademarks were not valued as tradenames and trademarks will not be maintained going forward. To value the developed software and technology, the Company utilized the relief from royalty method, a form of the income approach to value the developed software and technology which assumes a limited technology life and market share adjusted by assumed obsolescence with a terminal value. The referral base was valued using a multi-period excess earnings method, a form of the income approach. The Company utilized the with and without method, a form of the income approach to value non-compete agreements with Generex. The preliminary amounts assigned to the identifiable intangible assets, the estimated useful lives, and the estimated amortization expense related to these identifiable intangible assets are as follows: Preliminary Fair Value Average Estimated Life Developed Software/Technology $ 780,000 5 Referral Base 3,920,000 15 Non-compete agreements 2,410,000 3 $ 7,110,000 Intangible assets are generally amortized on a straight-line basis over the useful lives of the assets. Goodwill initially represented the excess of the purchase price over the fair market value of net assets acquired. Goodwill for Veneto Acquisition was $8.9 million as of the date of the First Closing and $16.3 million as of the date of the Second Closing. Based on the Amended Agreement (the “ Amendment During the quarter ending April 30, 2019, the amounts assigned to the identifiable intangible assets, the estimated useful lives, and the estimated amortization expense related to these identifiable intangible assets were revalued as follows: Preliminary Fair Value Average Estimated Life Developed Software/Technology $ 397,000 5 Referral Base 10,000 15 Non-compete agreements 1,870,000 3 $ 2,277,000 Regentys and Olaregen: On January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest in both Regentys Corporation (“Regentys”) and Olaregen Therapeutix Inc. (“Olaregen”). The Company accounted for the acquisitions of both Regentys and Olaregen as business combinations using the purchase method of accounting as prescribed in Accounting Standards Codification 805, Business Combinations (“ASC 805”) and ASC 820 – Fair Value Measurements and Disclosures (“ASC 820”). In accordance with ASC 805 and ASC 820, the Company used its best estimates and assumptions to accurately assign fair value to the tangible assets acquired, identifiable intangible assets and liabilities assumed as of the acquisition dates. Goodwill as of the acquisition date is measured as the excess of purchase consideration over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed. The fair values assigned to Regentys’ and Olaregen’s tangible and identifiable intangible assets acquired, and liabilities assumed are based on management’s estimates and assumptions. The estimated fair values of these assets acquired, and liabilities assumed are considered preliminary and are based on the information that was available as of the date of the acquisition. The preliminary estimated fair values of assets acquired, and liabilities assumed, and identifiable intangible assets may be subject to change as additional information is received. Thus, the provisional measurements of fair value are subject to change. The Company expects to finalize the valuations as soon as practicable, but not later than one year from the closing date. Regentys: On November 28, 2018, Generex and Regentys closed the acquisition of 51% of the outstanding capital stock of Regentys for a total consideration of fifteen million dollars ($15,000,000). On January 7, 2019 the Company completed a definitive Stock Purchase Agreement and related documents effecting the transactions contemplated by the LOI. Pursuant to a Stock Purchase Agreement between the Company and Regentys (the “Purchase Agreement”) the Company acquired 12,048,161 newly issued shares of the Regentys common stock representing 51% percent of the issued and outstanding capital stock of Regentys (“Regentys Shares”). In addition to $400,000 paid to Regentys upon signing of the LOI, the purchase price for the Regentys Shares will consist of the following cash payments, with the proceeds intended to be used for specific purposes, as noted: • $3,450,000 to initiate pre-clinical activities on or before January 15, 2018. As of the date this quarterly report was filed, the Company has paid $650,000 and the remaining balance of $2,800,000 is payable on or before June 30, 2019 per extension in amended agreement. • $2,000,000 to initiate patient recruitment activities on or before May 1, 2019. As of the date this quarterly report was filed, the Company has not yet paid this installment and the full balance of $2,000,000 is payable on or before June 30, 2019 per extension in amended agreement. • $3,000,000 to initiate a first-in-human pilot study on or before September 1, 2019. • $5,000,000 to initiate a human pivotal study on or before February 1, 2020. • $1,150,000 to submit a 510(k) de novo submission to the FDA on or about February 1, 2021. The Company issued its Promissory Note in the amount of $14,600,000 (the “Note’) representing its obligation to pay the above amounts. The Note is secured by a pledge of the Regentys shares pursuant to a Pledge and Security Agreement. In the event that Generex does not make any of the first three payments listed above, at Regentys’ option either: • Generex will forfeit all of the Regentys shares issued with no refund of amounts paid; or • Generex will issue shares of its common stock to Regentys equivalent to 110% of the value of the missing payment, which shares will be registered for resale. In the event Generex does not make either or both of the fourth and fifth payments, its share ownership of Regentys will be proportionately reduced. On March 14, 2019, the Company and Regentys amended the Stock Purchase Agreement and Promissory Note to extend the due date of the remaining balance of the first tranche of Guaranteed Payments amounting to $2,800,000 on or before April 1, 2019. On May 22, 2019, the Company and Regentys signed a second extension to extend the due date on or before June 30, 2019. The extensions of the due date have no impact on the existing schedule of future payments or any additional terms within the Note. Regentys has not filed any notice of default as of the date of publication, and Generex continues to provide Regentys with business opportunities continuing the relationship. Fair Value of the Regentys Acquisition The following table summarizes the allocation of the preliminary purchase price as of the Regentys acquisition: Preliminary Allocations as of January 7, 2019 Cash and cash equivalents $ 61,857 Other current assets 13,138 Property and equipment, net 444 Accounts payable and accrued liabilities (1,181,375 ) Notes payable (639,009 ) Loans from related parties (16,506 ) In-process research & development 3,510,680 Deferred tax liability (889,782 ) Total Fair Value of Assets Acquired 859,447 Consideration: Note receivable from Generex 14,345,205 Goodwill $ 13,485,758 The redeemable non-controlling interest of $4,073,898, representing the Series Stock A, was determined by deducting the total consideration paid of $14,745,205 from the total purchase value totaling $28,689,865 based on a convergence method in an Option Pricing Model using the Regentys capital structure with 12,048,161 newly issued shares of the Regentys common stock representing 51% percent of the issued and outstanding capital stock of Regentys. See Note 7 – Redeemable Non-Controlling Interest. Olaregen: On November 27, 2018, Generex and Olaregen entered into a binding letter of intent (“LOI”) contemplating the Company’s acquisition of 51% of the outstanding capital stock of Olaregen for a total consideration of twelve million dollars ($12,000,000). As of January 7, 2019, the Company completed a definitive Stock Purchase Agreement (“Purchase Agreement”) and related documents effecting the transactions contemplated by the LOI. The Company acquired 3,282,632 newly issued shares of the Olaregen common stock representing 51% percent of the issued and outstanding capital stock of Olaregen (“Olaregen Shares”). In addition to $400,000 paid to Olaregen upon signing of the LOI, the purchase price for the Olaregen Shares will consist of the following cash payments: • $800,000 on or before January 15, 2019. The Company has paid this installment. • $800,000 on or before January 31, 2019. As of the date this quarterly report was filed, the Company has paid $438,500 of this installment and remaining balance of $361,500 is payable on or before June 30, 2019 per extension in amended agreement. • $3,000,000 on or before April 1, 2019. As of the date this quarterly report was filed, the Company has not yet paid this installment and the full balance of $3,000,000 is payable on or before June 30, 2019 per extension in amended agreement. • $1,000,000. On or before May 31, 2019. As of the date this quarterly report was filed, the Company has not yet paid this installment and the full balance of $1,000,000 is payable on or before June 30, 2019 per extension in amended agreement. • $6,000,000.00 on or before September 30, 2019. The Company issued its Promissory Note in the amount of $11,600,000 (the “Note’) representing its obligation to pay the above amounts. The Note is secured by a pledge of the Olaregen shares pursuant to a Pledge and Security Agreement. In the event that Generex fails to pay the installment due on September 30, 2019, Generex will forfeit the shares allocated to that installment (1,600,000 Olaregen shares) and Olaregen will be entitled to “claw back” fifty percent (50%) of any and all shares paid for by the prior payments. On March 14, 2019, the Company and Olaregen amended the Stock Purchase Agreement and Promissory Note to extend the due date of the remaining balance of the second tranche of Guaranteed Payments amounting to $600,000 on or before April 1, 2019. The Company remitted additional payments of $200,000 on April 30, 2019 and $38,500 on May 17, 2019. On May 22, 2019, the Company and Olaregen amended the agreement to extend the due date of the remaining balance of the second tranche of Guaranteed Payments amounting to $361,500, the full balance of the third tranche amounting to $3,000,000 and the full balance of the fourth tranche amounting to $1,000,000 (total of $4,361,500) on or before June 30, 2019. The extensions of the due date have no impact on the existing schedule of future payments or any additional terms within the Note. Olaregen has not filed any notice of default as of the date of publication, and Generex continues to provide Olaregen with business opportunities continuing the relationship. In the event Generex does not make any other payments, its share ownership of Olaregen will be proportionately reduced. Based on the Note, in the event any incremental payment is not paid when due, Olaregen has the option to increase the per share purchase price for all remaining purchased shares to $4.00 per share. Based on $1,400,000 of remitted payments and a Promissory Note balance of $10,400,000 prior to the first extension agreement on March 14, 2019, Olaregen elected the option to proportionally increase the per share purchase price to $4.00 for the remaining 2,899,658 of the total 3,282,632 shares to be acquired. The resulting penalty amounts to an additional $998,633 which has been accrued for the Company to remit to Olaregen pursuant to the acquisition. Generex has a limited anti-dilution right under the Purchase Agreement, to ensure that Generex will retain 51% ownership in Olaregen for a period of time. Fair Value of the Olaregen Acquisition The following table summarizes the allocation of the preliminary purchase price as of the Olaregen acquisition: Preliminary Allocation as of January 7, 2019 Cash and cash equivalents $ 608,419 Prepaid expenses 20,488 Inventory 408,501 Other current assets 37,950 Accounts payable (216,670 ) Accrued liabilities (216,694 ) In-process research & development 3,980,000 Non-compete agreement 790,000 Deferred tax liability (1,040,173 ) Total Fair Value of Assets Acquired $ 3,844,925 Consideration: Cash paid prior to the time of closing 400,000 Note receivable from Generex 11,472,663 Goodwill $ 8,027,738 The components of the acquired intangible assets were as follows: Preliminary Fair Value Average Estimated Life In-process research and development $ 3,980,000 — Non-compete agreement 790,000 3 $ 4,770,000 Deferred Tax Liability As a result of the acquisition of Regentys and Olaregen, the purchase price allocation attributed to deferred tax liability was $889,782 and $1,040,173, respectfully. The Company has deferred tax assets of over $64 million with a full allowance equally to the to the amount of the deferred tax asset. Although the Company deferred tax assets are in excess of deferred tax liabilities totaling $1,929,955, the Company cannot offset the deferred tax liabilities against its deferred tax assets since the Company acquired less than the 80% of both Regentys and Olaregen preventing the Company to consolidate its income tax returns with Regentys and Olaregen for tax purposes. Therefore, the deferred tax liabilities will be reported separately until such time that the Company determines otherwise. In addition, the Company acquired approximately 51% of each of Regentys and Olaregen, less than the 80% required to permit the Company to consolidate with Regentys and Olaregen for tax purposes. Therefore, the deferred tax liabilities will be reported separately until such time that the Company determines otherwise. Unaudited Supplemental Pro Forma Data Unaudited pro forma results of operations for the nine months ended April 30, 2019 and 2018 as though the Company acquired Veneto, Olaregen and Regentys (the “Acquired Companies”) on the first day of each fiscal year are set forth below. Nine months Ended April 30 2019 2018 Revenues $ 9,434,017 $ 30,045,595 Cost of revenues 4,151,810 12,011,144 Gross profit 5,282,207 18,034,451 Operating expenses 12,597,408 20,674,120 Operating loss (7,315,201 ) (2,639,669 ) Other income (expense) 245,096 (85,809 ) Net loss (7,070,105 ) (2,725,478 ) Net loss attributable to noncontrolling interests (1,712,060 ) (123,379 ) Net loss available to common stockholders (5,358,045 ) (2,602,099 ) Comprehensive net loss $ (5,358,045 ) $ (2,602,099 ) Basic and diluted net loss per common share (0.09 ) (0.12 )

Inventory

Inventory	9 Months Ended
	Apr. 30, 2019
Inventory Disclosure [Abstract]
Inventory	Note 10 – Inventory Inventory consists of the following components: April 30, July 31, 2019 2018 Raw materials $ 108,060 $ — Finished goods 141,961 12,075 Total Inventory $ 250,021 $ 12,075

Property and Equipment

Property and Equipment	9 Months Ended
	Apr. 30, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 11 – Property and Equipment Property and equipment, net consisted of the following: April 30, July 31, 2019 2018 Computers and technological assets $ 168,286 $ 11,365 Machinery and equipment 373,803 — Furniture and fixtures 76,988 19,879 Leasehold Improvements 47,144 21,501 666,221 52,745 Less accumulated depreciation (109,945 ) (21,209 ) $ 556,276 $ 31,536 Depreciation expense related to property and equipment for the nine months ended April 30, 2019 and April 30, 2018 was $150,744 and $15,016, respectively. For the nine months ended April 30, 2019, the Company had $252,012 of disposals and $11,208 of impairment of long-lived assets. The $252,012 of disposals pertains to Veneto and was mostly the result of their shift in business operations during March 2019 described in Notes 1 and 2. The $11,208 impairment of long-lived assets pertains to Grainland Pharmacies Holdings, LLC which ceased to operate – see Note 9.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Apr. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Note 12 – Goodwill and Intangible Assets Goodwill and Intangible Assets The change in the carrying amount of goodwill and other intangible assets for the year ended July 31, 2018 and nine-month period ended April 30, 2019, is as follows: Total Goodwill Other Intangibles, net Balance as of July 31, 2018 $ 3,187,757 $ — $ 3,187,757 Acquisition of Veneto (revaluation) 15,898,371 13,585,769 2,312,602 Purchase of intangible assets 26,488 — 26,488 Disposal of intangible assets (62,091 ) — (62,091 ) Acquisition of Regentys 16,996,438 13,485,758 3,510,680 Acquisition of Olaregen 12,797,737 8,027,737 4,770,000 Close of Grainland Pharmacy (88,311 ) — (88,311 ) Amortization of Veneto developed software/technology (39,700 ) — (39,700 ) Amortization of Veneto referral base (initial valuation) (333 ) — (333 ) Amortization of Veneto non-compete agreement (initial valuation) (311,667 ) — (311,667 ) Amortization of Olaregen non-compete agreement (81,525 ) — (81,525 ) Balance as of April 30, 2019 $ 48,323,164 $ 35,099,264 $ 13,223,900 Intangible assets are generally amortized on a straight-line basis over the useful lives of the assets. The Company is currently not amortizing the in-process research and development until it becomes commercially viable and placed in service. At the time when the intangible assets are placed in service the Company will determine a useful life. Goodwill represents the excess of the purchase price over the fair market value of net assets acquired. Goodwill for NGDx was $13.4 million as of the date of the acquisition. When the acquisition transaction closed in January 2017, NGDx was a development-stage entity and its liabilities exceeded the aggregate value of its assets. Utilizing discounted cash flow (DCF) valuation methodology, Generex determined that NGDx has forecasted losses throughout the reasonably foreseeable future with a nominal terminal value. In addition, there was a high degree of uncertainty as to the future cash flows of NGDx. Therefore, the Company concluded that the implied goodwill arising out of the acquisition was zero and should be properly characterized as fully impaired as of July 31, 2018. Goodwill for Veneto was $8,883,982 during first closing and $16,293,948 during the second closing for total goodwill of $25,177,930 pertaining to the acquisition. Based on the Amended Agreement (the “ Amendment

Notes Payable

Notes Payable	9 Months Ended
	Apr. 30, 2019
Debt Disclosure [Abstract]
Notes Payable	Note 13 – Notes Payable On October 26, 2018, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell and sold its Note Due October 26, 2019 (“Note”) in the principal amount of $682,000 . On November 25, 2018, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell and sold its Note Due November 26, 2019 (“Note”) in the principal amount of $1,060,000. The purchase price of the Note was $1,000,000. The remaining $60,000 of principal amount represents original issue discount. The Note does not bear any stated interest in addition to the original issue discount. On January 24, 2019, Generex entered into Securities Purchase Agreements with three investors pursuant to which the Company agreed to sell and sold convertible notes bearing interest at 10% per annum (the “Notes”) in the aggregate principal amount of $2,110,000. The purchase price of the Notes was $2,010,000 and the remaining $100,000 of principal amount represents original issue discount. Pursuant to the Securities Purchase Agreements, Generex also sold warrants to the investors to purchase up to an aggregate 120,570 shares of common stock with the fair value of the warrants as of the date of issuance in excess of the Notes (Note 14) resulting in full discount of the Notes. On February 4, 2019, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell and sold a convertible note bearing interest at 10% per annum (the “Note”) in the principal amount of $750,000. The purchase price of the Note was $712,500 and the remaining $37,500 of principal amount represents original issue discount. Pursuant to the Securities Purchase Agreements, the Company also sold to the Investor warrants to purchase up to an aggregate 45,000 shares of common stock with the fair value of the warrants as of the date of issuance in excess of the Notes (Note 14) resulting in full discount of the Notes. On February 15, 2019, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell and sold a convertible note bearing interest at 10% per annum (the “Note”) in the principal amount of $750,000 . On April 8, 2019, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell and sold a convertible note bearing interest at 10% per annum (the “Note”) in the principal amount of $530,000 . On April 23, 2019, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell and sold a convertible note bearing interest at 10% per annum (the “Note”) in the principal amount of $530,000 . For the three months ended April 30, 2019, the Company issued 279,111 to investors of convertible notes disclosed above. For the nine months ended April 30, 2019, the Company issued 15,483,681 warrants which consisted of 399,681 issued to investors of convertible notes disclosed above, 15,000,000 issued to a former shareholder of NGDx upon acquisition of the remaining 49% interest of the entity (Note 9) and 84,000 issued to AEXG in connection with an arbitrator’s award (Note 4). With the exception of the 84,000 warrants issued to AEXG, all other granted warrants vested immediately upon issuance. Pursuant to its wholly owned subsidiary NuGenerex, the Company completed the acquisition of the assets and 100% of the membership interests of two pre-operational pharmacies, Empire State Pharmacy Holdings, LLC and Grainland Pharmacy Holdings, LLC, pursuant to the bills of sale for a consideration of $320,000 Promissory Note. Refer to Note 9 for details. Pursuant to the second closing of the acquisition of certain operating assets of Veneto Holdings, L.L.C. and its affiliates, Generex’s wholly owned subsidiary agreed to assume outstanding debt of Veneto subsidiaries to Compass Bank, including obligations under a term loan and a revolving line of credit. Claiming three separate types of default, Compass Bank has demanded payment in full of amounts due under the term loan and revolving line of credit, in an aggregate amount of approximately $3,404,000. Generex believes it has defenses to such demand, including that the bank was not an intended beneficiary of the subsidiary’s agreement to assume the debt. Pursuant to its acquisition of Regentys, the Company inherited convertible notes with several investors which collectively holds a principal plus discount balance of $611,761 and has accrued interest of $12,899 as of April 30, 2019.

Derivative Liability

Derivative Liability	9 Months Ended
	Apr. 30, 2019
Notes to Financial Statements
Derivative Liability	Note 14 – Derivative Liability The Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted and all additional convertible debentures and warrants are included in the value of the derivative. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative liabilities on the issuance date. Based on the various convertible notes described in Note 13, the fair value of applicable derivative liabilities on notes, warrants and change in fair value of derivative liability are as follows as of April 30, 2019: Note Date of Issuance Convertible Note Balance Derivative Liability on Convertible Notes Derivative Liability on Warrants Change in FV of Derivative Liability A January 24, 2019 $ 2,110,000 $ 1,757,644 $ 56,707 $ 874,184 B February 4, 2019 750,000 618,349 3,660 192,037 C February 15, 2019 750,000 571,659 48,586 52,437 D April 8, 2019 530,000 496,701 77,992 4,001 E April 23, 2019 530,000 493,160 70,533 7,508 Totals $ 4,670,000 $ 3,937,513 $ 257,478 $ 1,130,167 Note A Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price determined as follows: the lesser of • A price determined as of the date of closing; and • 70% of the lowest volume weighted average trading price of the common stock on the ten days prior to conversion. Note B Subject to certain ownership limitations, the Note will be convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price determined as follows: the lesser of • Average price for the ten days prior to closing; and • 70% of the lowest volume weighted average trading price of the common stock on the ten days prior to conversion. Note C Subject to certain ownership limitations, the Note will be convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price determined as follows: the lesser of • $2.50 per share; and • 70% of the lowest volume weighted average trading price of the common stock on the ten days prior to the date a notice of conversion is received. Note D Subject to certain ownership limitations, the Note will be convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price determined as follows: the lesser of • A price determined as of the date of closing; and • 70% of the lowest volume weighted average trading price of the common stock on the ten days prior to (and including) the date a notice of conversion is received. Note E Subject to certain ownership limitations, the Note will be convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price determined as follows: the lesser of • A price determined as of the date of closing; and • 70% of the lowest volume weighted average trading price of the common stock on the ten days prior to (and including) the date a notice of conversion is received. As a result of the Amended Agreement entered into on March 28, 2019 (“the Amendment

Income Taxes

Income Taxes	9 Months Ended
	Apr. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Note 15 – Income Taxes: The Company has incurred losses since inception, which have generated net operating loss (“NOL”) carryforwards. The NOL carryforwards arise from both United States and Canadian sources. Pre-tax gain or (loss) arising from domestic operations (United States) were $(5,415,726) and $35,948,698 for the nine months ended April 30, 2019 and the year ended July 31, 2018, respectively. Pre-tax (losses) arising from foreign operations (Canada) were $(339,586) and $(150,394) for the nine months ended April 30, 2019 and the year ended July 31, 2018, respectively. As of April 30, 2019, the Company has NOL carryforwards in Generex Biotechnology Corporation of approximately $215 million, of which $200 million will expire in 2019 through 2037, and $14.8 million will not expire. The non-expiring portion is limited to 80% of the current year taxable income of the respective entity. Generex Pharmaceuticals Inc. has NOL carryforwards of approximately $36.4 million, which expire in 2024 through 2039. Antigen Express, Inc. has NOL carryforwards of approximately $36.7 million, of which $35.1 will expire in 2019 through 2038. Regentys Corporation has NOL carryforwards of approximately $6.1 million, of which $3.5 million will expire in 2033 through 2038. Olaregen Therapeutics, Inc. has NOL carryforwards of $1.6 million which will not expired. Some of these loss carryforwards are subject to limitation due to the acquisition of Regentys, Olaregen and Antigen and may be limited in future years due to certain structural ownership changes which have occurred over the last several years related to the Company’s equity and convertible debenture financing transactions. As of April 30, 2019, the Company had no tax benefits which have not been fully allowed for, and no adjustment to its financial position, results of operations or cash flows was required. The Company has deferred tax assets of over $67 million with a full allowance equally to the to the amount of the deferred tax asset. The Company does not expect that unrecognized tax benefits will increase within the next twelve months. As referenced in Note 9, the acquisition of Regentys and Olaregen resulted in the purchase price allocation attributed to deferred tax liability was $889,782 and $1,040,173, respectfully. Although the Company deferred tax assets are in excess of deferred tax liabilities totaling $1,929,955, the Company cannot offset the deferred tax liabilities against its deferred tax assets since the Company acquired less than the 80% of both Regentys and Olaregen preventing the Company to consolidate its income tax returns with Regentys and Olaregen for tax purposes. Therefore, the deferred tax liabilities will be reported separately until such time that the Company determines otherwise. The Company records interest and penalties related to tax matters within other expense on the accompanying consolidated statement of operations. These amounts are not material to the consolidated financial statements for the years presented. Generally, tax years 2015 to 2018 remain open to examination by the Internal Revenue Agency or other tax jurisdictions to which the Company is subject. The Company’s Canadian tax returns are subject to examination by federal and provincial taxing authorities in Canada. Generally, tax years 2010 to 2018 remain open to examination by the Canada Revenue Agency or other tax jurisdictions to which the Company is subject.

Subsequent Events

Subsequent Events	9 Months Ended
	Apr. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 16 - Subsequent Events: The Company has evaluated subsequent events occurring after the balance sheet date through the date the unaudited condensed interim consolidated financial statements were issued. On May 10, 2019, 4,000,000 shares of Generex common stock was transferred out of the Friends of Generex Biotechnology Investment Trust (the “Trust”) in consideration of 592,683 Series A voting preferred of Olaregen held by an existing shareholder in Olaregen. A $2,000,000 promissory note from Genrex to the existing shareholder in Olaregen remains outstanding. The 592,683 represents approximately 10% voting control of Olaregen. The $2,000,000 was extended to have a maturity date of August 1, 2019. Subsequent to this transaction, there are 2,366,187 Olaregen shares that belong to non-controlling interest shareholders which represents a 37.9% non-controlling interest. On May 10, 2019, the Trust transferred 400,000 shares of Generex common stock to an investor to to satisfy a $1,000,000 obligation. On May 22, 2019, the Company and Olaregen amended the Stock Purchase Agreement and Promissory Note to extend the due date of the remaining balance of the second payment and the full balance of the third and fourth guaranteed payments amounting to $4,361,500 on or before June 30, 2019. On May 22, 2019, the Company and Regentys amended the Stock Purchase Agreement and Promissory Note to extend the due date of the remaining balance of the first tranche of and the full balance of the second guaranteed payments amounting to $4,800,000 on or before June 30, 2019.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Apr. 30, 2019
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Revenue from the pharmacy services is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient using common carrier or delivered by the pharmacies own personnel). At the time of dispensing each pharmacy has a contract with the insurance payor (item (i)); the insurance payor has accepted the claim for reimbursement from the pharmacy (item ii) and informed the pharmacy how much will be paid for the prescription (item (iii)); the insurance payor is now legally obligated to make payment on the accepted claim within a given period proscribed by statute (item (iv)); and, the prescription has been taken from the pharmacy inventory, placed into an individually labeled container specific to the patient, and the patient is able to take possession of the prescription (item (v)). Shipment to or pick up by the patient is the first time that all criteria for revenue recognition have been met. Revenue from the laboratory services is recognized upon the completion of accessions (the requested laboratory test has been performed and the report has been issued to the requesting physician). After the test has been performed and reported, the insurance company and/or patient has an obligation to pay for medically necessary laboratory tests (items (i) and (ii)). Unlike the pharmacy services model, laboratory services are provided prior to insurance company approval; as a result, the seller’s price to buyer is not known until payment is provided (items (iii) and (iv). Based on historical collections, the Company estimates the expected revenues associated with similar tests and recognizes the revenue when testing results have been provided (v). Revenue from the provision of management services is recognized in accordance with the contractual terms of the relationship (item i); however, the current agreements in place typically specify that a percentage of the gross margin associated with the third-parties’ sales that the Company facilitates is to be remitted (iii), and as such, the revenue is considered earned upon completion of the third parties’ sales of such products (iv). Like pharmacy services described above, revenue is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient using common carrier or delivered by the pharmacies own personnel) (v). Provisions for estimated sales returns and uncollectible accounts are recorded in the period in which the related sales are recognized based on historical and anticipated rates. The Company determines whether it is the principal or agent for its retail pharmacy contract services on a contract by contract basis. In the majority of its contracts, the Company has determined it is the principal due to it: (i) being the primary obligor in the arrangement, (ii) having latitude in changing the product or performing part of the service, (iii) having discretion in supplier selection, (iv) having involvement in the determination of product or service specifications, and (v) having credit risk. The Company’s obligations under its client contracts for which revenues are reported using the gross method are separate and distinct from its obligations to the third-party pharmacies included in its retail pharmacy network contracts. Pursuant to these contracts, the Company is contractually required to pay the third-party pharmacies in its retail pharmacy network for products sold, regardless of whether the Company is paid by its clients. The Company’s responsibilities under its client contracts typically include validating eligibility and coverage levels, communicating the prescription price and the co-payments due to the third-party retail pharmacy, identifying possible adverse drug interactions for the pharmacist to address with the prescriber prior to dispensing, suggesting generic alternatives where clinically appropriate, and approving the prescription for dispensing. Although the Company does not have credit risk with respect to Retail Co-Payments or inventory risk related to retail network claims, management believes that all of the other applicable indicators of gross revenue reporting are present. For contracts under which the Company acts as an agent, revenue is recognized using the net method. In March 2019, the Company changed its business model to no longer utilize their existing pharmacies. This shift resulted in breaking their existing lease agreements with their pharmacies which resulted in a liability of $606,296 as of April 30, 2019 and disposing the majority of applicable leasehold improvements, reduction of employees and no longer holding and selling inventory. Going forward Veneto will conduct business exclusively through their management services organization and by entering into more ancillary provider service agreements with third party pharmacies as an effort to reduce fixed costs and salaries. This was made practicable due to the decrease in overall script volume coupled with delays in the Company being able to receive operating licenses from various government agencies.
Cost of Goods Sold	Cost of Goods Sold
Income Taxes	Income Taxes
Inventories	Inventories
Property and Equipment	Property and Equipment Leasehold improvements The shorter of the expected useful life of the improvement or the lease term Computers and technological assets 3-5 years Machinery and equipment 3-5 years Furniture and fixtures 3-7 years Assets acquired through finance lease arrangements or long-term rental arrangements that transfer substantially all the risks and rewards associated with ownership of the asset to the Company (as lessee) are capitalized.
Reclassifications to Prior Period Financial Statements and Adjustments	Reclassifications to Prior Period Financial Statements and Adjustments Certain reclassifications have been made in the Company’s condensed interim consolidated financial statements of the prior year to conform to the current year presentation. These reclassifications have no impact on previously reported net income.
Redeemable Non-Controlling Interest	Redeemable Non-Controlling Interest As a result of the acquisition of Regentys with redeemable convertible preferred stock classified as a mezzanine instrument outside of the its equity accounts, such amounts are reclassified as redeemable non-controlling interest as the carrying value determined by the purchase price allocation at the time of the acquisition of Regentys.
Derivative Financial Instruments	Derivative Financial Instruments As a result of the early adoption of ASU 2017-11 in the second quarter of the fiscal year ended April 30, 2019, the Company has no derivative financials instruments with down round features classified as a liability at April 30, 2019.
Adoption of New Accounting Standards	Adoption of New Accounting Standards We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effective dates during the periods reported and in future periods. The Company does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. • ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” • ASC 815-40 (formerly SFAS No. 133 “Accounting for derivative instruments and hedging activities”), requires that embedded derivative instruments be bifurcated and assessed, along with free-standing derivative instruments such as warrants, on their issuance date and in accordance with ASC 815-40-15 (formerly EITF-00-19 “Accounting for derivative financial instruments indexed to, and potentially settled in, a company’s own stock”) to determine whether they should be considered a derivative liability and measured at their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option pricing formula and present value pricing. At April 30, 2019, the Company adjusted its derivative liability to its fair value, and reflected the change in fair value, in its condensed interim consolidated statement of operations and comprehensive loss. • ASU 2016-08 “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net).” • ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing.” • ASU 2016-11, “Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF (Emerging Issue Task Force) Meeting.” • ASU 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.” • ASU 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers.” • ASU 2018-07, “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” • ASU 2017-13, “Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840) and Leases (Topic 842). Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and Rescission of Prior SEC Staff Announcements and Observer Comments.” The standards provide companies with a single model for use in accounting for revenue arising from contracts with customers that supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the model is to recognize revenue when control of the goods or services transfers to the customer, as opposed to recognizing revenue when the risks and rewards transfer to the customer under the existing revenue guidance. The guidance permits companies to either apply the requirements retrospectively to all prior periods presented, or apply the requirements in the year of adoption, through a cumulative adjustment. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The guidance was adopted as of August 1, 2018. The Company found that the adoption did not have a material effect on the Company’s condensed interim consolidated financial statements and related disclosures. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments—Overall: Recognition and Measurement of Financial Assets and Financial Liabilities In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. The guidance was adopted as of August 1, 2018 and did not have a material effect on the Company’s condensed interim consolidated financial statements and related disclosures. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, In January 2017, the FASB issued ASU 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business.” These amendments clarify the definition of a business. The amendments affect all companies and other reporting organizations that must determine whether they have acquired or sold a business. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The amendments are intended to help companies and other organizations evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This update is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The guidance was adopted as of August 1, 2018 and did not have a material effect on the Company’s condensed interim consolidated financial statements and related disclosures. In May 2017, the FASB issued ASU 2017-09, “Compensation-Stock Compensation” (Topic 718): Scope of Modification Accounting. The amendments provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718 Compensation-Stock Compensation. An entity should account for the effects of a modification unless all the following are met: 1. The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification. 2. The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified. 3. The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The ASU is effective for all entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. The guidance was adopted as of August 1, 2018 and did not have a material effect on the Company’s condensed interim consolidated financial statements and related disclosures.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In February 2016, the FASB issued ASU No. 2016-02, Leases In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. Topic 480, Distinguishing Liabilities from Equity In February 2018, the FASB issued ASU 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement”, which adds disclosure requirements to Topic 820 for the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for interim and annual reporting periods beginning after December 15, 2019. The Company is evaluating the effect that ASU 2018-13 will have on its condensed interim consolidated financial statements.

Net Income Per Share (EPS) (Tab

Net Income Per Share (EPS) (Tables)	9 Months Ended
	Apr. 30, 2019
Accounting Policies [Abstract]
Computation of diluted EPS	The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was 4,902,125 for the three and nine months ended April 30, 2019. Three Months Ended April 30, Three Months Ended April 30, 2019 2018 Weighted average number of common shares outstanding - Basic 60,362,163 22,430,100 Potentially dilutive common stock equivalents — 32,016,936 Weighted average number of common and equivalent shares outstanding-Diluted 60,362,163 54.447,036 Nine Months Ended April 30, Nine Months Ended April 30, 2019 2018 Weighted average number of common shares outstanding - Basic 44,203,218 22,430,100 Potentially dilutive common stock equivalents — 32,016,936 Weighted average number of common and equivalent shares outstanding-Diluted 44,,203,218 54.447,036

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Apr. 30, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Common stock options granted, forfeited or expired and exercised	The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan: Options Weighted Average Exercise Price per Share Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding - July 31, 2018 232,218 $ 1.46 0.22 380,247 Granted 6,650,625 0.56 Forfeited or expired (1,364,168 ) (0.37 ) Exercised — — Outstanding - April 30, 2019 5,518,675 $ 0.68 9.15 3,157,178
Fair value assumptions used in Black-Scholes option-pricing	The following assumptions were used in the Black-Scholes option-pricing model: April 30, 2019 Exercise price $0.64 – 1.85 Expected term 5 to 10 years Risk-free interest rate 2.56% - 3.15 % Estimated volatility 135.2% - 222.2 % Expected dividend — Stock price at valuation date $0.64 – $1.85

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Apr. 30, 2019
Net purchase price of NGDx	The net purchase price of NGDx was determined to be as follows: Stock Price at Closing Shares Fair Value Purchase price: Common Stock at closing $ .23 1,117,011 $ 253,721 Common Stock after closing $ .23 420 95 Common Stock post reverse stock split $ .23 4,830,000 1,097,100 Total purchase price 5,947,431 $ 1,350,916
Fair Value Assumptions Used in Accounting for Warrants	The key inputs used in the fair value calculations were as follows: December 1, 2018 July 31, 2018 Exercise price 2.50 2.50 Time to expiration 3.14 years 3.47 years Risk-free interest rate 3.01 % 2.77 % Estimated volatility 138.61 % 143.97 % Dividend — — Stock price at valuation date $ 0.9 $ 0.1
Fair Value Assumptions Used in Accounting for Call Options	The following assumptions were used in estimating the value of the Call Option: December 1, 2018 July 31, 2018 Risk-free interest rate 2.52 % 2.44 % Estimated volatility 164.43 % 129.95 % Remaining Term 1.13 years 1.47 years Stock price at valuation date $ 0.9043 $ 0.0976
Purchase price allocated as of acquisition date	The final allocation of the purchase price as of January 31, 2019, is as follows: Preliminary Allocation as of December 28, 2017 Allocation Adjustments Final Allocation Intangible assets (licenses) $ 276,380 $ — $ 276,380 Property and equipment 19,879 — 19,879 Computer software acquired 5,980 — 5,980 Leasehold Improvements 17,761 — 17,761 Total assets acquired 320,000 — 320,000 Consideration: Note Payable 320,000 320,000 Goodwill $ — $ —
Schedule of Finite-Lived Intangible Assets	The components of the acquired intangible assets were as follows: Preliminary Fair Value Average Estimated Life In-process research and development $ 3,980,000 — Non-compete agreement 790,000 3 $ 4,770,000
Supplemental Pro Forma	Unaudited pro forma results of operations for the nine months ended April 30, 2019 and 2018 as though the Company acquired Veneto, Olaregen and Regentys (the “Acquired Companies”) on the first day of each fiscal year are set forth below. Nine months Ended April 30 2019 2018 Revenues $ 9,434,017 $ 30,045,595 Cost of revenues 4,151,810 12,011,144 Gross profit 5,282,207 18,034,451 Operating expenses 12,597,408 20,674,120 Operating loss (7,315,201 ) (2,639,669 ) Other income (expense) 245,096 (85,809 ) Net loss (7,070,105 ) (2,725,478 ) Net loss attributable to noncontrolling interests (1,712,060 ) (123,379 ) Net loss available to common stockholders (5,358,045 ) (2,602,099 ) Comprehensive net loss $ (5,358,045 ) $ (2,602,099 ) Basic and diluted net loss per common share (0.09 ) (0.12 )
Veneto Holdings, L.L.C.
Summary of Acquisition	The following table summarizes the allocation of the preliminary purchase price as of the Veneto acquisition as of the First Closing and the Second Closing: “First Closing” completed on October 3, 2018 “Second Closing” completed on November 1, 2018 Total Cash and cash equivalents $ 2,410,150 $ — $ 2,410,150 Accounts receivable, net 1,935,078 — 1,935,078 Inventory, net 1,068,856 — 1,068,856 Prepaid expenses 95,804 — 95,804 Property and equipment, net 652,590 — 652,590 Other receivables 1,014,316 — 1,014,316 Notes receivable - LT 1,387,763 — 1,387,763 Other assets, net 25,745 — 25,745 Intangible assets, net 35,603 7,110,000 7,145,603 Total assets acquired 8,625,905 7,110,000 15,735,905 Total current liabilities 2,509,887 — 2,509,887 Notes payable — 3,403,948 3,403,948 Total liabilities assumed 2,509,887 3,403,948 5,913,835 Net identifiable assets acquired 6,116,018 3,706,052 9,822,070 Goodwill 8,883,982 16,293,948 25,177,930 Total consideration transferred $ 15,000,000 $ 20,000,000 $ 35,000,000 The following table summarizes the allocation of the revalued purchase price as of the Veneto acquisition as of the First Closing and the Second Closing during the quarter ending April 30, 2019: “First Closing” completed on October 3, 2018 “Second Closing” completed on November 1, 2018 Total Cash and cash equivalents $ 2,410,150 $ — $ 2,410,150 Accounts receivable, net 1,430,638 — 1,490,638 Inventory, net 1,068,856 — 1,068,856 Prepaid expenses 95,804 — 95,804 Property and equipment, net 652,590 — 652,590 Other receivables 1,014,316 — 1,014,316 Notes receivable - LT 1,387,763 — 1,387,763 Other assets, net 25,745 — 25,745 Intangible assets, net 35,603 2,277,000 2,312,603 Total assets acquired 8,181,465 2,277,000 10,458,465 Total current liabilities 2,065,448 — 2,065,448 Notes payable — 3,403,948 3,403,948 Total liabilities assumed 2,065,448 3,403,948 5,469,396 Net identifiable assets acquired 6,116,017 (1,126,948 ) 4,989,069 Goodwill 13,585,769 Total consideration tranferred $ — $ — $ 18,574,838
Estimated amortization expense	The preliminary amounts assigned to the identifiable intangible assets, the estimated useful lives, and the estimated amortization expense related to these identifiable intangible assets are as follows: Preliminary Fair Value Average Estimated Life Developed Software/Technology $ 780,000 5 Referral Base 3,920,000 15 Non-compete agreements 2,410,000 3 $ 7,110,000 During the quarter ending April 30, 2019, the amounts assigned to the identifiable intangible assets, the estimated useful lives, and the estimated amortization expense related to these identifiable intangible assets were revalued as follows: Preliminary Fair Value Average Estimated Life Developed Software/Technology $ 397,000 5 Referral Base 10,000 15 Non-compete agreements 1,870,000 3 $ 2,277,000
Regentys
Summary of Acquisition	The following table summarizes the allocation of the preliminary purchase price as of the Regentys acquisition: Preliminary Allocations as of January 7, 2019 Cash and cash equivalents $ 61,857 Other current assets 13,138 Property and equipment, net 444 Accounts payable and accrued liabilities (1,181,375 ) Notes payable (639,009 ) Loans from related parties (16,506 ) In-process research & development 3,510,680 Deferred tax liability (889,782 ) Total Fair Value of Assets Acquired 859,447 Consideration: Note receivable from Generex 14,345,205 Goodwill $ 13,485,758
Olaregen
Summary of Acquisition	The following table summarizes the allocation of the preliminary purchase price as of the Olaregen acquisition: Preliminary Allocation as of January 7, 2019 Cash and cash equivalents $ 608,419 Prepaid expenses 20,488 Inventory 408,501 Other current assets 37,950 Accounts payable (216,670 ) Accrued liabilities (216,694 ) In-process research & development 3,980,000 Non-compete agreement 790,000 Deferred tax liability (1,040,173 ) Total Fair Value of Assets Acquired $ 3,844,925 Consideration: Cash paid prior to the time of closing 400,000 Note receivable from Generex 11,472,663 Goodwill $ 8,027,738

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Apr. 30, 2019
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following components: April 30, July 31, 2019 2018 Raw materials $ 108,060 $ — Finished goods 141,961 12,075 Total Inventory $ 250,021 $ 12,075

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Apr. 30, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment, net consisted of the following: April 30, July 31, 2019 2018 Computers and technological assets $ 168,286 $ 11,365 Machinery and equipment 373,803 — Furniture and fixtures 76,988 19,879 Leasehold Improvements 47,144 21,501 666,221 52,745 Less accumulated depreciation (109,945 ) (21,209 ) $ 556,276 $ 31,536

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Apr. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the carrying amount of goodwill and other intangible assets	The change in the carrying amount of goodwill and other intangible assets for the year ended July 31, 2018 and nine-month period ended April 30, 2019, is as follows: Total Goodwill Other Intangibles, net Balance as of July 31, 2018 $ 3,187,757 $ — $ 3,187,757 Acquisition of Veneto (revaluation) 15,898,371 13,585,769 2,312,602 Purchase of intangible assets 26,488 — 26,488 Disposal of intangible assets (62,091 ) — (62,091 ) Acquisition of Regentys 16,996,438 13,485,758 3,510,680 Acquisition of Olaregen 12,797,737 8,027,737 4,770,000 Close of Grainland Pharmacy (88,311 ) — (88,311 ) Amortization of Veneto developed software/technology (39,700 ) — (39,700 ) Amortization of Veneto referral base (initial valuation) (333 ) — (333 ) Amortization of Veneto non-compete agreement (initial valuation) (311,667 ) — (311,667 ) Amortization of Olaregen non-compete agreement (81,525 ) — (81,525 ) Balance as of April 30, 2019 $ 48,323,164 $ 35,099,264 $ 13,223,900

Derivative Liability (Tables)

Derivative Liability (Tables)	9 Months Ended
	Apr. 30, 2019
Notes to Financial Statements
Derivative Liability	Based on the various convertible notes described in Note 13, the fair value of applicable derivative liabilities on notes, warrants and change in fair value of derivative liability are as follows as of April 30, 2019: Note Date of Issuance Convertible Note Balance Derivative Liability on Convertible Notes Derivative Liability on Warrants Change in FV of Derivative Liability A January 24, 2019 $ 2,110,000 $ 1,757,644 $ 56,707 $ 874,184 B February 4, 2019 750,000 618,349 3,660 192,037 C February 15, 2019 750,000 571,659 48,586 52,437 D April 8, 2019 530,000 496,701 77,992 4,001 E April 23, 2019 530,000 493,160 70,533 7,508 Totals $ 4,670,000 $ 3,937,513 $ 257,478 $ 1,130,167

Organization of Business and _2

Organization of Business and Going Concern (Details Narrative) - USD ($)	Jan. 07, 2019	Apr. 30, 2019	Oct. 03, 2018	Jan. 18, 2017
Accumulated deficit		$ (413,941,958)
Working capital deficiency		$ 25,000,000
Secured promissory note Description	On January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest in both Regentys Corporation (“Regentys”) and Olaregen Therapeutix Inc. (“Olaregen”). Regentys is a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York based regenereative medicine company that is preparing to lauch its proprietary, patented, wound conforming gel matrix, Excellagen, an FDA 510K Cleared wound healing product. The terms of the Regentys acquisition included on upfront payment of $400,000, plus $14,600,000 to be paid according to a milestone-based schedule. The terms of the Olaregen acquisition included on upfront payment of $400,000, plus $11,600,000 to be paid according to a milestone-based schedule.
Veneto Holdings, L.L.C.
Secured promissory note			$ 15,000,000
Hema Diagnostic Systems, LLC
Majority interest				51.00%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	9 Months Ended
	Apr. 30, 2019	Jul. 31, 2018
Liability	$ 606,296
Deferred tax liability	889,782	$ 1,040,173
Write down of inventory	$ 645,351
Machinery and Equipment [Member]
Estimated useful lives	3-5 years
Furniture and Fixtures [Member]
Estimated useful lives	3-7 years
Computers and technological assets [Member]
Estimated useful lives	3-5 years

Loan from Related Parties (Deta

Loan from Related Parties (Details Narrative) - USD ($)	1 Months Ended
	Jan. 18, 2019	Jul. 31, 2018
Berkman
Agreement terms	Pursuant to the January 18, 2017 Acquisition, Mr. Berkman, previous owner of NGDx and debt holder, agreed, under certain conditions to transfer the remaining 49% of the NGDx equity to the Company for a consideration of $1.00. On December 1, 2018, the Company and Mr. Berkman entered into an Agreement, Assignment and Release, pursuant to which Mr. Berkman transferred the remaining NGDx equity interests to the Company, waiving and releasing any conditions to such transfer. NGDx is now a wholly owned subsidiary of the Company. In addition to the assignment of the NGDx interests, Mr. Berkman released these loans in exchange for shares of the Company’s common stock valued at the aggregate of such amount using the closing price for the common stock on November 30, 2018. The closing price was $18.99, resulting in 32,881 shares issuable to Mr. Berkman. This transaction resulted in Mr. Berkman’s advances of $624,404 plus the loan and call option which resulted in additional paid in capital of $13,431,705 which was reclassified to the Company’s stockholders’ equity as an extinguishment of debt for $14,056,109.
Hema Diagnostic Systems, LLC
Interest rate		0.75%
Outstanding balance		$ 13,239,837
Accrued interest		$ 191,869

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)

Dec. 02, 2018

Nov. 27, 2019

Aug. 22, 2017

Dec. 31, 2011

Apr. 30, 2019

Nov. 16, 2012

Apr. 23, 2019

Apr. 08, 2019

Feb. 15, 2019

Feb. 04, 2019

Jan. 24, 2019

Nov. 25, 2018

Oct. 26, 2018

Jul. 31, 2018

Commitments and Contingencies

The letter from AEXG counsel claimed that Generex’s acceptance of $3,000,000 in financing from Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney’s fees and costs.

Rental payments, 2019

$ 44,700

Rental Payment, 2020

82,469

Rental payment, 2021

$ 9,403

Litigation awards for damages

$ 315,695

Litigation awards, exercisable shares

84,000

Exercise price

$ 2.50

Note amount

$ 530,000

$ 530,000

$ 750,000

$ 750,000

$ 2,110,000

$ 1,060,000

$ 682,000

Value of the warrants

$ 65,613

Liquidated damages

220,000

Accrued Liquidated damages

$ 285,613

Alternative Execution Group [Member]

Memorandum of Understanding description

The petition includes a demand of $3,300,360 as the value of the Warrants. The arbitrator did not award the specific amount of $3.3 million, but only liquidated damages in the amount of $220,000 and the value of 84,000 warrants “as of today” (the date of the award) plus attorney’s fees, certain costs, prejudgment and post-judgment interest (which continues to run on a daily basis) and arbitration fees. Generex has responded that the value of the warrants on the date of the award is $0 or some figure far less than the value calculated by AEXG. The petition to confirm the arbitrator’s award and Generex’s opposition are pending before the Court for a decision.

Olaregen

Intellectual property acquired

$ 650,000

Damages for Unpaid Invoices

Value of damages sought

$ 429,000

Lawsuit filing date

31-Dec-11

Name of Plaintiff

Vendor

Settlement of litigation

$ 125,000

Interest per annum, failure to pay settlement

3.00%

Fixed cost per annum, failure to pay settlement

$ 25,000

Breach of contract and detinue

Counterclaim proceeding

$ 200,000

Net (Loss) _ Income Per Share (

Net (Loss) / Income Per Share (“EPS”) - Computation of diluted EPS (Details) - shares	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Accounting Policies [Abstract]
Weighted average number of common shares outstanding - Basic	60,362,163	22,430,100	44,203,218	22,430,100
Potentially dilutive common stock equivalents		32,016,936		32,016,936
Weighted average number of common and equivalent shares outstanding-Diluted	60,362,163	54.447036	44,203,218	54.447036

Net (Loss)_ Income Per Share (_

Net (Loss)/ Income Per Share (“EPS”) (Details Narrative) - shares	3 Months Ended	9 Months Ended
	Apr. 30, 2019	Apr. 30, 2019
Accounting Policies [Abstract]
Weighted average number of common stock equivalents not included in diluted income per share	16,016,231	16,016,231

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Jan. 07, 2019	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018	Dec. 01, 2018	Nov. 30, 2018	Nov. 27, 2018	Oct. 26, 2018	Jul. 31, 2018	Mar. 27, 2017	Feb. 09, 2017	Jan. 18, 2017
Common stock issued		60,362,163		60,362,163					4,830,000	22,430,121		2,179,989	1,117,011
Acquisition in HDS													51.00%
Shares of common stock, obligated to issue													4,830,000
Common stock payable, Shares				1,238,517
Common stock payable, Amount				$ 201,294
Net (loss) attributable to noncontrolling interests		$ (839,419)	$ (103,794)	(1,199,822)	$ (313,261)
Investment in subsidiary by noncontrolling interest		44,020	$ 213,403	228,789	$ 213,403
Non-controlling interest		$ 21,958,757		$ 21,958,757						$ (5,576,272)
Series I Convertible Preferred Stock
Convertible preferred stock, shares authorized		6,000		6,000						6,000
Convertible preferred stock, par value (in dollars per share)		$ 0.001		$ 0.001						$ 0.001
Convertible preferred stock, shares issued		0		0						6,000
Convertible preferred stock shares issued value										$ 1
Series H Convertible Preferred Stock
Common stock issued upon conversion of preferred stock		25,200,000		25,200,000
Convertible preferred stock, shares authorized		109,000		109,000						109,000
Convertible preferred stock, par value (in dollars per share)		$ 0.001		$ 0.001						$ 0.001
Convertible preferred stock, shares issued		0		0						63,000	63,000
Convertible preferred stock shares issued value										$ 3	$ 3,000,000
Regentys Series A Redeemable Convertible Preferred Stock [Member]
Convertible preferred stock, shares authorized		2,793,192		2,793,192						2,793,192
Convertible preferred stock, par value (in dollars per share)		$ 0.0001		$ 0.0001						$ 0.0001
Convertible preferred stock shares issued value
Olaregen Series A Preferred Stock [Member]
Convertible preferred stock, shares authorized		592,683		592,683						0
Convertible preferred stock, par value (in dollars per share)		$ 0.001		$ 0.001						$ 0.001
Convertible preferred stock, shares issued		592,683		592,683						0
Convertible preferred stock shares issued value
Hema Diagnostic Systems, LLC
Net (loss) attributable to noncontrolling interests				(122,692)
Investment in subsidiary by noncontrolling interest				$ 133,679
B-H Sanford, LLC
Common stock issued upon conversion of preferred stock						25,200,000
Salvo
Common stock issued upon conversion of preferred stock							3,354,645
Moscato
Common stock issued upon conversion of preferred stock							3,276,000
Remain To Be Issued
Common stock issued										349,545
Olaregen
Non-controlling interest								$ (11,999,559)
LOI Terms	Pursuant to the Company’s acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632 shares of Olaregen common stock. As of January 31, 2019, Olaregen had a total of 5,648,819 shares of common stock and 592,683 Series A voting preferred stock for a total of 6,241,502 total voting shares outstanding. As such, there are 2,958,870 of shares that belong to non-controlling interest shareholders which represents a 47.41% non-controlling interest.
Regentys
Non-controlling interest	$ (9,870,762)
LOI Terms	Pursuant to the Company’s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161 shares of Regentys common stock. As of January 31, 2019, Regentys had a total of 18,623,278 shares of common stock and 2,793,192 Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest.
Net Purchase Price
Common stock issued													5,947,431
After Closing
Common stock issued													420
At Closing
Common stock issued													1,117,011
Post Reverse Stock Split
Common stock issued													4,830,000

Redeemable Non-Controlling In_2

Redeemable Non-Controlling Interest (Details Narrative) - USD ($)	Apr. 30, 2019	Jul. 31, 2018
Notes to Financial Statements
Redeemable Non-Controlling Int	$ 4,073,898

Stock-Based Compensation - Comm

Stock-Based Compensation - Common stock options granted, forfeited or expired and exercised (Details) - USD ($)	9 Months Ended	12 Months Ended
	Apr. 30, 2019	Jul. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options Outstanding, Beginning	232,218
Options Granted	6,650,625
Options Forfeited or expired	(1,364,168)
Options Exercised
Options Outstanding, End	5,518,675	232,218
Weighted Average Exercise Price per Share, Beginning	$ 1.46
Weighted Average Exercise Price per Share, Granted	0.56
Weighted Average Exercise Price per Share, Forfeited or expired	(0.37)
Weighted Average Exercise Price per Share, Exercised
Weighted Average Exercise Price per Share, End	$ 0.68	$ 1.46
Weighted Average Remaining Life (Years)	9 years 1 month 24 days	2 months 19 days
Aggregate Intrinsic Value	$ 3,157,178	$ 380,247

Stock-Based Compensation - Fair

Stock-Based Compensation - Fair value assumptions used in Black-Scholes option-pricing (Details)	9 Months Ended
	Apr. 30, 2019$ / shares
Expected dividend
Maximum [Member]
Exercise price	$ 1.85
Expected term	10 years
Risk-free interest rate	3.15%
Estimated volatility	222.20%
Stock price at period end date	$ 1.85
Minimum [Member]
Exercise price	$ 0.64
Expected term	5 years
Risk-free interest rate	2.56%
Estimated volatility	135.20%
Stock price at period end date	$ 0.64

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Jul. 31, 2018
Outstanding options	5,518,675		232,218
Market value	$ 1.14
Compensation expense	$ 1,530,312
Options granted	6,650,625
Stock Options
Outstanding options	5,518,675
Outstanding options, weighted average remaining contractual term	9 years 1 month 24 days
Compensation expense	$ 1,530,312
Unrecognized compensation costs	$ 1,728,688
Options granted	6,650,625
Stock Option Plan 2017
Common stock reserved for future issuance	240,000,000
Common stock reserved for future awards	234,492,875
Stock Option Plan 2019
Common stock reserved for future issuance	1,200,000
Common stock reserved for future awards	1,200,000
Stock Option Plan 2006
Common stock reserved for future issuance	2,835,000
Common stock reserved for future awards	2,823,450
Options vested	2,345,175

Acquisitions - Net purchase pri

Acquisitions - Net purchase price of NGDx (Details) - USD ($)	6 Months Ended
	Jan. 18, 2017	Apr. 30, 2019	Oct. 26, 2018	Jul. 31, 2018	Feb. 09, 2017
Purchase price:
Shares	1,117,011	60,362,163	4,830,000	22,430,121	2,179,989
After Closing
Purchase price:
Stock Price at Closing	$ 0.23
Shares	420
Fair Value	$ 95
Post Reverse Stock Split
Purchase price:
Stock Price at Closing	$ 0.23
Shares	4,830,000
Fair Value	$ 1,097,100
Net Purchase Price
Purchase price:
Shares	5,947,431
Fair Value	$ 1,350,916
At Closing
Purchase price:
Stock Price at Closing	$ 0.23
Shares	1,117,011
Fair Value	$ 253,721

Acquisitions - Fair Value Assum

Acquisitions - Fair Value Assumptions Used in Accounting for Warrants (Details) - $ / shares	Dec. 01, 2018	Apr. 30, 2019	Jul. 31, 2018
Dividend
Call Option
Risk-free interest rate	2.52%		2.44%
Estimated volatility	164.43%		129.95%
Stock price at period end date	$ 0.9043		$ 0.0976
Warrant
Exercise price	$ 2.50		$ 2.50
Time to expiration	3 years 1 month 20 days		3 years 5 months 20 days
Risk-free interest rate	3.01%		2.77%
Estimated volatility	138.61%		143.97%
Dividend
Stock price at period end date	$ 0.9		$ 0.1

Acquisitions - Fair Value Ass_2

Acquisitions - Fair Value Assumptions Used in Accounting for Call Options (Details) - $ / shares	Dec. 01, 2018	Jul. 31, 2018
Call Option
Risk-free interest rate	2.52%	2.44%
Estimated volatility	164.43%	129.95%
Remaining Term	1 year 1 month 16 days	1 year 5 months 20 days
Stock price at valuation date	$ 0.9043	$ 0.0976
Warrant
Risk-free interest rate	3.01%	2.77%
Estimated volatility	138.61%	143.97%
Stock price at valuation date	$ 0.9	$ 0.1

Acquisitions - Purchase price a

Acquisitions - Purchase price allocated as of acquisition date (Details) - USD ($)	Apr. 30, 2019	Jan. 07, 2019	Nov. 27, 2018	Nov. 02, 2018	Oct. 03, 2018	Dec. 28, 2017	Jan. 18, 2017
Intangible assets						$ 276,380
Property and Equipment						19,879
Computer software acquired						5,980
Leasehold Improvements						17,761
Total Assets Acquired						320,000
Consideration:
Note Payable						320,000
Goodwill						$ 0	$ 13,400,000
"Veneto First Closing"
Intangible assets	$ 35,603				$ 35,603
Consideration:
Goodwill					$ 8,883,982
Allocation Adjustments
Intangible assets	0
Property and Equipment	0
Computer software acquired	0
Leasehold Improvements	0
Total Assets Acquired	0
Final Allocation
Intangible assets	276,380
Property and Equipment	19,879
Computer software acquired	5,980
Leasehold Improvements	17,761
Total Assets Acquired	320,000
Consideration:
Note Payable	320,000
Goodwill	0
Total1Member
Intangible assets	2,312,603
Consideration:
Goodwill	13,585,769
"Veneto Second Closing"
Intangible assets	2,277,000			$ 7,110,000
Consideration:
Goodwill				16,293,948
Total
Intangible assets	7,145,603
Consideration:
Goodwill	$ 25,177,930
Regentys
Consideration:
Goodwill		$ 13,485,758
Olaregen
Consideration:
Goodwill			$ 8,027,738
Veneto Holdings, L.L.C.
Consideration:
Goodwill				$ 13,538,629

Acquisitions - Summary of Acqui

Acquisitions - Summary of Acquisition (Details) - USD ($)	Apr. 30, 2019	Jan. 07, 2019	Nov. 27, 2018	Nov. 02, 2018	Oct. 03, 2018	Jul. 31, 2018	Apr. 30, 2018	Dec. 28, 2017	Jul. 31, 2017	Jan. 18, 2017
Cash and cash equivalents	$ 1,407,837					$ 1,046,365	$ 1,567,433		$ 2,879,165
Accounts receivable, net	1,803,192					33,555
Inventory, net	250,021					12,075
Property and equipment, net	556,276					31,536
Other assets, net	29,421					7,824
Intangible assets, net								$ 276,380
Total current liabilities	28,839,953					25,229,015
Notes payable	7,029,049					$ 320,000
Goodwill								$ 0		$ 13,400,000
Total
Cash and cash equivalents	2,410,150
Accounts receivable, net	1,935,078
Inventory, net	1,068,856
Prepaid expenses	95,804
Property and equipment, net	652,590
Other receivables	1,014,316
Notes receivable - LT	1,387,763
Other assets, net	25,745
Intangible assets, net	7,145,603
Total assets acquired	15,735,905
Total current liabilities	2,509,887
Notes payable	3,403,948
Total liabilities assumed	5,913,835
Net identifiable assets acquired	9,822,070
Goodwill	25,177,930
Total consideration transferred	35,000,000
"Veneto First Closing"
Cash and cash equivalents	2,410,150				$ 2,410,150
Accounts receivable, net	1,430,638				1,935,078
Inventory, net	1,068,856				1,068,856
Prepaid expenses	95,804				95,804
Property and equipment, net	652,590				652,590
Other receivables	1,014,316				1,014,316
Notes receivable - LT	1,387,763				1,387,763
Other assets, net	25,745				25,745
Intangible assets, net	35,603				35,603
Total assets acquired	8,181,465				8,625,905
Total current liabilities	2,065,448				2,509,887
Notes payable
Total liabilities assumed	2,065,448				2,509,887
Net identifiable assets acquired	6,116,017				6,116,018
Goodwill					8,883,982
Total consideration transferred					$ 15,000,000
Final Allocation
Intangible assets, net	276,380
Goodwill	0
Allocation Adjustments
Intangible assets, net	0
Total1Member
Cash and cash equivalents	2,410,150
Accounts receivable, net	1,490,638
Inventory, net	1,068,856
Prepaid expenses	95,804
Property and equipment, net	652,590
Other receivables	1,014,316
Notes receivable - LT	1,387,763
Other assets, net	25,745
Intangible assets, net	2,312,603
Total assets acquired	10,458,465
Total current liabilities	2,065,448
Notes payable	3,403,948
Total liabilities assumed	5,469,396
Net identifiable assets acquired	4,989,069
Goodwill	13,585,769
Total consideration transferred	18,574,838
"Veneto Second Closing"
Cash and cash equivalents
Accounts receivable, net
Inventory, net
Prepaid expenses
Property and equipment, net
Other receivables
Notes receivable - LT
Other assets, net
Intangible assets, net	2,277,000			7,110,000
Total assets acquired	2,277,000			7,110,000
Total current liabilities
Notes payable	3,403,948			3,403,948
Total liabilities assumed	3,403,948			3,403,948
Net identifiable assets acquired	(1,126,948)			3,706,052
Goodwill				16,293,948
Total consideration transferred				20,000,000
Regentys
Cash and cash equivalents		$ 61,857
Property and equipment, net		444
Notes payable		639,009
Net identifiable assets acquired		859,447
Goodwill		$ 13,485,758
Olaregen
Cash and cash equivalents			$ 608,419
Inventory, net			408,501
Prepaid expenses			20,488
Net identifiable assets acquired			3,844,925
Goodwill			$ 8,027,738
Veneto Holdings, L.L.C.
Goodwill				$ 13,538,629

Acquisitions - Estimated amorti

Acquisitions - Estimated amortization expense (Details) - USD ($)	Oct. 03, 2019	Apr. 30, 2019	Nov. 27, 2018
Preliminary Fair Value
Developed Software/Technology	$ 780,000	$ 397,000
Referral Base	3,920,000	10,000
Non-compete agreements	2,410,000	1,870,000
Total	$ 7,110,000	$ 2,277,000
Olaregen
Developed Software/Technology			$ 3,980,000
Non-compete agreements			790,000
Total			$ 4,770,000

Acquisitions - Purchase price_2

Acquisitions - Purchase price as of the Regentys acquisition (Details) - USD ($)	Apr. 30, 2019	Jan. 07, 2019	Nov. 27, 2018	Nov. 02, 2018	Oct. 03, 2018	Jul. 31, 2018	Apr. 30, 2018	Dec. 28, 2017	Jul. 31, 2017	Jan. 18, 2017
Cash and cash equivalents	$ 1,407,837					$ 1,046,365	$ 1,567,433		$ 2,879,165
Other current assets	218,819					96,251
Property and equipment, net	556,276					31,536
Accounts payable and accrued liabilities	(19,863,047)					(11,044,774)
Notes payable	(7,029,049)					$ (320,000)
Goodwill								$ 0		$ 13,400,000
Total
Cash and cash equivalents	2,410,150
Property and equipment, net	652,590
Notes payable	(3,403,948)
Total Fair Value of Assets Acquired	9,822,070
Goodwill	25,177,930
"Veneto Second Closing"
Cash and cash equivalents
Property and equipment, net
Notes payable	(3,403,948)			(3,403,948)
Total Fair Value of Assets Acquired	(1,126,948)			3,706,052
Goodwill				16,293,948
Final Allocation
Goodwill	0
Total1Member
Cash and cash equivalents	2,410,150
Property and equipment, net	652,590
Notes payable	(3,403,948)
Total Fair Value of Assets Acquired	4,989,069
Goodwill	13,585,769
"Veneto First Closing"
Cash and cash equivalents	2,410,150				$ 2,410,150
Property and equipment, net	652,590				652,590
Notes payable
Total Fair Value of Assets Acquired	$ 6,116,017				6,116,018
Goodwill					$ 8,883,982
Regentys
Cash and cash equivalents		$ 61,857
Other current assets		13,138
Property and equipment, net		444
Accounts payable and accrued liabilities		(1,181,375)
Notes payable		(639,009)
Loans from related parties		(16,506)
In-process research & development		3,510,680
Deferred tax liability		(889,782)
Total Fair Value of Assets Acquired		859,447
Note receivable from Generex		14,345,205
Goodwill		$ 13,485,758
Olaregen
Cash and cash equivalents			$ 608,419
Other current assets			37,950
In-process research & development			3,980,000
Deferred tax liability			(1,040,173)
Total Fair Value of Assets Acquired			3,844,925
Note receivable from Generex			11,472,663
Goodwill			$ 8,027,738
Veneto Holdings, L.L.C.
Goodwill				$ 13,538,629

Acquisitions - Purchase price_3

Acquisitions - Purchase price as of the Olaregen acquisition (Details) - USD ($)	Apr. 30, 2019	Jan. 07, 2019	Nov. 27, 2018	Nov. 02, 2018	Oct. 03, 2018	Jul. 31, 2018	Apr. 30, 2018	Dec. 28, 2017	Jul. 31, 2017	Jan. 18, 2017
Cash and cash equivalents	$ 1,407,837					$ 1,046,365	$ 1,567,433		$ 2,879,165
Inventory	250,021					12,075
Other current assets	218,819					$ 96,251
Goodwill								$ 0		$ 13,400,000
Total
Cash and cash equivalents	2,410,150
Prepaid expenses	95,804
Inventory	1,068,856
Total Fair Value of Assets Acquired	9,822,070
Goodwill	25,177,930
"Veneto Second Closing"
Cash and cash equivalents
Prepaid expenses
Inventory
Total Fair Value of Assets Acquired	(1,126,948)			3,706,052
Goodwill				16,293,948
Final Allocation
Goodwill	0
Total1Member
Cash and cash equivalents	2,410,150
Prepaid expenses	95,804
Inventory	1,068,856
Total Fair Value of Assets Acquired	4,989,069
Goodwill	13,585,769
"Veneto First Closing"
Cash and cash equivalents	2,410,150				$ 2,410,150
Prepaid expenses	95,804				95,804
Inventory	1,068,856				1,068,856
Total Fair Value of Assets Acquired	$ 6,116,017				6,116,018
Goodwill					$ 8,883,982
Regentys
Cash and cash equivalents		$ 61,857
Other current assets		13,138
In-process research & development		3,510,680
Deferred tax liability		(889,782)
Total Fair Value of Assets Acquired		859,447
Note receivable from Generex		14,345,205
Goodwill		$ 13,485,758
Olaregen
Cash and cash equivalents			$ 608,419
Prepaid expenses			20,488
Inventory			408,501
Other current assets			37,950
Accounts payable			(216,670)
Accrued liabilities			(216,694)
In-process research & development			3,980,000
Non-compete agreement			790,000
Deferred tax liability			(1,040,173)
Total Fair Value of Assets Acquired			3,844,925
Cash paid prior to the time of closing			400,000
Note receivable from Generex			11,472,663
Goodwill			$ 8,027,738
Veneto Holdings, L.L.C.
Goodwill				$ 13,538,629

Acquisitions - Intangible asset

Acquisitions - Intangible assets (Details) - USD ($)	Oct. 03, 2019	Apr. 30, 2019	Nov. 27, 2018
Preliminary Fair Value
Developed Software/Technology	$ 780,000	$ 397,000
Non-compete agreements	2,410,000	1,870,000
Total	$ 7,110,000	$ 2,277,000
Olaregen
Developed Software/Technology			$ 3,980,000
Non-compete agreements			790,000
Total			$ 4,770,000

Acquisitions - Unaudited Supple

Acquisitions - Unaudited Supplemental Pro Forma Data (Details) - USD ($)	9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017
Business Combinations [Abstract]
Revenues	$ 9,434,017	$ 30,045,595
Cost of revenues	4,151,810	12,011,144
Gross profit	5,282,207	18,034,451
Operating expenses	12,597,408	20,674,120
Operating loss	(7,315,201)	(2,639,669)
Other income (expense)	245,096	(85,809)
Net loss	(7,070,105)	(2,725,478)
Net loss attributable to noncontrolling interests	(1,712,060)	(123,379)
Net loss available to common stockholders	(5,358,045)	(2,602,099)
Comprehensive net loss	$ (5,358,045)	$ (2,602,099)
Basic and diluted net loss per common share	$ (0.09)	$ (0.12)

Acquisitions (Details Narrative

Acquisitions (Details Narrative) - USD ($)

May 22, 2019

Nov. 02, 2018

Oct. 03, 2018

May 22, 2019

Apr. 30, 2019

Nov. 28, 2018

Nov. 27, 2018

Dec. 28, 2017

Apr. 30, 2019

Apr. 30, 2018

Jan. 18, 2017

Apr. 30, 2019

Apr. 30, 2018

Apr. 23, 2019

Apr. 08, 2019

Feb. 15, 2019

Feb. 04, 2019

Jan. 07, 2019

Dec. 01, 2018

Oct. 26, 2018

Jul. 31, 2018

Feb. 09, 2017

Acquisition of interest

51.00%

Acquisition of outstanding limited liability company units

4,950

Value of shares exchanged for outstanding limited liability units

$ 253,721

Common stock issued

60,362,163

60,362,163

1,117,011

60,362,163

4,830,000

22,430,121

2,179,989

Limited liability company units receied

300

Call Option

$ 13,431,706

Call option recorded as an asset

$ 2,168,211

Changes in fair value of contingent purchase consideration

$ 4,573,493

15,147,591

$ 23,350,122

Warrant issued to acquire stock

15,000,000

Common stock, price per year

$ 2.50

Total consideration

$ 1,350,916

Intangible assets acquired

2,911,377

Aggregate purchase price

$ 1

Promissory Note

$ 320,000

Promissory Note, Due Date

Jun. 28, 2018

Promissory Note, interest rate

3.00%

10.00%

10.00%

10.00%

10.00%

27.50%

Goodwill impairment

$ 99,519

Business combination description

On November 1, 2018 we consummated the acquisition of the Second Closing Assets, consisting primarily of Veneto’s management services organization business and two additional ancillary services. The aggregate price for the First Closing Assets and the Second Closing Assets was $30,000,000. The Company issued a promissory note in the principal amount of $35,000,000 (the “New Note”) consisting of the $30,000,000 purchase price and a $5,000,000 original issue discount, as the sole consideration payable on the Second Closing Date. In addition, we agreed to assume approximately $3.8 million in outstanding institutional debt of Veneto subsidiaries, but will have use of Veneto cash which would otherwise have been applied to paying down the debt.

Payment of Promissory Note

$ 320,000

$ 320,000

Subsequent Event [Member]

Payment of Promissory Note

$ 4,361,500

$ 4,800,000

Berkman

Common stock, price per year

$ 2.50

Shares exercisable

15,000,000

Veneto Holdings, L.L.C.

Business combination description

The aggregate purchase price for the Assets, is $35,000,000 including the Promissory Note. At the Second Closing, the Company will pay the principal of the Promissory Note plus interest to Veneto, (i) $9,000,000 will be paid by the Company into a trust or other fiduciary account acceptable to Veneto to be used exclusively for satisfaction of certain contingent liabilities of Veneto and subsidiaries of Veneto not being acquired by the Company, (ii) $3,000,000 will be paid by the Company into an escrow account to secure potential obligations of Veneto in respect of the Second Closing date working capital and under the indemnification provisions of the Agreement and (iii) the balance will be payable directly to Veneto in cash.

Olaregen

Business combination description

The Company will purchase 3,282,632 newly issued shares of the Olaregen common stock representing 51% percent of the issued and outstanding capital stock of Olaregen (“Olaregen Shares”).

LOI description

On November 27, 2018, Generex Biotechnology Corporation (the “Company”) and Olaregen Therapeutix Inc. (“Olaregen”) entered into a binding letter of intent (“LOI”) contemplating the Company’s acquisition of 51% of the outstanding capital stock of Olaregen for a total consideration of twelve million dollars ($12,000,000). As of January 7, 2019, the Company completed a definitive Stock Purchase Agreement (“Purchase Agreement”) and related documents effecting the transactions contemplated by the LOI.

Deferred tax liability

$ 1,040,173

Regentys

Acquisition of interest

51.00%

Business combination description

Pursuant to a Stock Purchase Agreement between the Company and Regentys (the “Purchase Agreement”) the Company purchased 12,048,161 newly issued shares of the Regentys common stock representing 51% percent of the issued and outstanding capital stock of Regentys (“Regentys Shares”). In addition to $400,000 paid to Regentys upon signing of the LOI, the purchase price for the Regentys Shares will consist of the following cash payments, with the proceeds intended to be used for specific purposes, as noted: • $3,450,000 to initiate pre-clinical activities on or before January 15, 2018. • $2,000,000 to initiate patient recruitment activities on or before May 1, 2019. • $3,000,000 to initiate a first-in-human pilot study on or before September 1, 2019. • $5,000,000 to initiate a human pivotal study on or before February 1, 2020. The Company issued its Promissory Note in the amount of $14,600,000 (the “Note’) representing its obligation to pay the above amounts. The Note is secured by a pledge of the Regentys pursuant to a Pledge and Security Agreement. In the event that Generex does not make any of the first three payments listed above, at Regentys’ option either: • Generex will forfeit all of the Regentys shares issued with no refund of amounts paid; or • Generex will issue shares of its common stock to Regentys equivalent to 110% of the value of the missing payment, which shares will be registered for resale.

LOI description

On November 28, 2018, Generex Biotechnology Corporation (the “Company”) and Regentys Corporation. (“Regentys”) closed the acquisition of 51% of the outstanding capital stock of Regentys for a total consideration of fifteen million dollars ($15,000,000). On January 7, 2019 the Company completed a definitive Stock Purchase Agreement and related documents effecting the transactions contemplated by the LOI.

Deferred tax liability

$ 889,782

Post Reverse Stock Split

Common stock issued

4,830,000

At Closing

Common stock issued

1,117,011

Net Purchase Price

Common stock issued

5,947,431

After Closing

Common stock issued

420

Inventory (Details)

Inventory (Details) - USD ($)	Apr. 30, 2019	Jul. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 108,060	$ 0
Finished goods	141,961	12,075
Total Inventory	$ 250,021	$ 12,075

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Apr. 30, 2019	Jul. 31, 2018
Property and equipment	$ 666,221	$ 52,745
Less accumulated depreciation	(109,945)	(21,209)
Property and equipment, net	556,276	31,536
Machinery and Equipment [Member]
Property and equipment	373,803
Furniture and Fixtures [Member]
Property and equipment	76,988	19,879
Computers and technological assets
Property and equipment	168,286	11,365
Leasehold Improvements [Member]
Property and equipment	$ 47,144	$ 21,501

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018
Depreciation expense	$ 150,744	$ 15,016
Disposal of assets	252,012
Impairment of long-lived assets	11,208
Grainland Pharmacies Holdings
Impairment of long-lived assets	11,208
Veneto Holdings, L.L.C.
Disposal of assets	$ 252,012

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Details) - USD ($)	9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018
Purchase of intangible assets	$ 26,487
Total
Balance at beginning	3,187,757
Purchase of intangible assets	26,488
Disposal of intangible assets	(62,091)
Close of Grainland Pharmacy	(88,311)
Balance at end	48,323,164
Goodwill
Balance at beginning	0
Purchase of intangible assets	0
Disposal of intangible assets	0
Close of Grainland Pharmacy	0
Balance at end	35,099,264
Other Intangibles, net
Balance at beginning	3,187,757
Purchase of intangible assets	26,488
Disposal of intangible assets	(62,091)
Close of Grainland Pharmacy	(88,311)
Balance at end	13,223,900
Veneto Holdings, L.L.C. | Total
Acquisition	15,898,371
Amortization of Veneto developed software/technology	(39,700)
Amortization of Veneto referral base	(333)
Amortization of Veneto non-compete agreement	(311,667)
Veneto Holdings, L.L.C. | Goodwill
Acquisition	13,585,769
Amortization of Veneto developed software/technology	0
Amortization of Veneto referral base	0
Amortization of Veneto non-compete agreement	0
Veneto Holdings, L.L.C. | Other Intangibles, net
Acquisition	2,312,602
Amortization of Veneto developed software/technology	(39,700)
Amortization of Veneto referral base	(333)
Amortization of Veneto non-compete agreement	(311,667)
Regentys | Total
Acquisition	16,996,438
Regentys | Goodwill
Acquisition	13,485,758
Regentys | Other Intangibles, net
Acquisition	3,510,680
Olaregen | Total
Acquisition	12,797,737
Amortization of Olaregen non-compete agreement	(81,525)
Olaregen | Goodwill
Acquisition	8,027,737
Amortization of Olaregen non-compete agreement	0
Olaregen | Other Intangibles, net
Acquisition	4,770,000
Amortization of Olaregen non-compete agreement	$ (81,525)

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Details Narrative) - USD ($)	Apr. 30, 2019	Jan. 07, 2019	Nov. 27, 2018	Nov. 02, 2018	Oct. 03, 2018	Dec. 28, 2017	Jan. 18, 2017
Goodwill						$ 0	$ 13,400,000
Final Allocation
Goodwill	$ 0
Total1Member
Goodwill	13,585,769
Total
Goodwill	$ 25,177,930
Regentys
Goodwill		$ 13,485,758
Olaregen
Goodwill			$ 8,027,738
Veneto Holdings, L.L.C.
Goodwill				$ 13,538,629
"Veneto Second Closing"
Goodwill				$ 16,293,948
"Veneto First Closing"
Goodwill					$ 8,883,982

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Apr. 30, 2019	Apr. 30, 2019	Apr. 23, 2019	Apr. 08, 2019	Feb. 15, 2019	Feb. 04, 2019	Jan. 24, 2019	Nov. 25, 2018	Oct. 26, 2018	Dec. 28, 2017
Debt Disclosure [Abstract]
Note amount			$ 530,000	$ 530,000	$ 750,000	$ 750,000	$ 2,110,000	$ 1,060,000	$ 682,000
Purchase price of note			505,500	505,500	712,500	712,500	2,010,000	1,000,000	550,000
Investor fee									15,000
Original issue discount			$ 25,000	$ 25,000	$ 37,500	$ 37,500	$ 100,000	$ 60,000	$ 147,000
Effective interest			10.00%	10.00%	10.00%	10.00%			27.50%	3.00%
Number of warrants sold			84,126	92,842	57,143	45,000	120,570
Payment of Promissory Note	$ 320,000	$ 320,000
Principal plus discount balance		611,761
Accrued interest		$ 12,899

Derivative Liability (Details)

Derivative Liability (Details)	9 Months Ended
	Apr. 30, 2019USD ($)
Convertible Note Balance	$ 4,670,000
Derivative Liability on Convertible Notes	3,937,513
Derivative Liability on Warrants	257,478
Change in FV of Derivative Liability	$ 1,130,167
Note B [Member]
Date of Issuance	Feb. 4, 2019
Convertible Note Balance	$ 750,000
Derivative Liability on Convertible Notes	618,349
Derivative Liability on Warrants	3,660
Change in FV of Derivative Liability	$ 192,037
Note C [Member]
Date of Issuance	Feb. 15, 2019
Convertible Note Balance	$ 750,000
Derivative Liability on Convertible Notes	571,659
Derivative Liability on Warrants	48,586
Change in FV of Derivative Liability	$ 52,437
Note D [Member]
Date of Issuance	Apr. 8, 2019
Convertible Note Balance	$ 530,000
Derivative Liability on Convertible Notes	496,701
Derivative Liability on Warrants	77,992
Change in FV of Derivative Liability	$ 4,001
Note E [Member]
Date of Issuance	Apr. 23, 2019
Convertible Note Balance	$ 530,000
Derivative Liability on Convertible Notes	493,160
Derivative Liability on Warrants	70,533
Change in FV of Derivative Liability	$ 7,508
Note A [Member]
Date of Issuance	Jan. 24, 2019
Convertible Note Balance	$ 2,110,000
Derivative Liability on Convertible Notes	1,757,644
Derivative Liability on Warrants	56,707
Change in FV of Derivative Liability	$ 874,184

Derivative Liability (Details N

Derivative Liability (Details Narrative)	9 Months Ended
	Apr. 30, 2019
Notes to Financial Statements
Derivative Liability description	Based on the valuation as of the date of agreement on March 28, 2019, an allocation of $6,424,338 was allocated to derivative liability for downside protection. As of April 30, 2019, the downside protection had a market change of $570,112 and held a value of $6,994,450.

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Apr. 30, 2019	Jul. 31, 2018
Pre-tax gain or (loss) arising from domestic operations	$ (5,415,726)	$ 35,948,698
Pre-tax (losses) arising from foreign operations	(339,586)	$ (150,394)
NOL carryforwards	215,000,000
Deferred tax assets	67,000,000
Deferred tax assets in excess of deferred tax liabilities	1,929,955
Generex Pharmaceuticals
NOL carryforwards	36,400,000
Antigen Express
NOL carryforwards	36,700,000
Regentys
NOL carryforwards	6,100,000
Deferred tax liability	889,782
Olaregen
NOL carryforwards	1,600,000
Deferred tax liability	$ 1,040,173

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	May 22, 2019	May 10, 2019	May 22, 2019	Apr. 30, 2019	Apr. 30, 2019
Payment of Promissory Note				$ 320,000	$ 320,000
Subsequent Event [Member]
Subsequent event description		On May 10, 2019, 4,000,000 shares of Generex common stock was transferred out of the Friends of Generex Biotechnology Investment Trust (the “Trust”) in consideration of 592,683 Series A voting preferred of Olaregen held by an existing shareholder in Olaregen. A $2,000,000 promissory note from Genrex to the existing shareholder in Olaregen remains outstanding. The 592,683 represents approximately 10% voting control of Olaregen. The $2,000,000 was extended to have a maturity date of August 1, 2019. Subsequent to this transaction, there are 2,366,187 Olaregen shares that belong to non-controlling interest shareholders which represents a 37.9% non-controlling interest.
Number of stock transferred		400,000
Obligation for stock transferred		$ 1,000,000
Payment of Promissory Note	$ 4,361,500		$ 4,800,000